Session Title: Highlights of the Day I Session Including Clinical Trials Participation and Public Service Awards  
Session Type: Highlights of the Day  
Track: Special Session  
Time: 7:30 AM - 9:00 AM  
Location: E Hall D1

- Chair  
  Douglas Yee, MD - Chair
- Award Recipient  
  John Carney
- Gynecologic Cancer  
  Rebecca Sophie Kristeleit, MD, PhD
- Cancer Prevention/Epidemiology  
  Jeffrey N. Weitzel, MD
- Pediatric Oncology  
  Jeffrey Toretsky, MD
- Breast Cancer - HER2/ER+  
  Michael Gnant, MD, FACS
- Discussion on Value of Cancer Care  
  Jennifer Malin, MD, PhD

Session Title: Training Program Directors' Breakfast  
Session Type: Education Session  
Track: Professional Development  
Time: 7:30 AM - 9:30 AM  
Location: S404

- Welcome and Introductions  
  Frances A. Collichio, MD - Chair
- ASCO University  
  Lisa Johnson, MHS, MT(ASCP)SC
• ASCO MedOnc In-Training Exam Statistics  
  *Timothy D. Gilligan, MD, MSc*
• Program Directors’ Retreat  
  *Jill Gilbert, MD*

**Session Title:** ASCO–American Cancer Society Award and Lecture  
**Session Type:** Special Session  
**Track:** Special Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S100a  
  • Carpe Diem: Time to Seize the Opportunity for Cancer Prevention  
    *Graham A. Colditz, MD, DrPH*

**Session Title:** Access to Data from Clinical Trials: A New Age of Clinical Trial Transparency  
**Session Type:** Education Session  
**Track:** Clinical Trials  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S100bc  
  • What We Stand to Gain and Lose: A Regulatory Perspective on Trial Transparency  
    *Tatiana Michelle Prowell, MD - Chair*
  • Patient Advocacy and Trial Transparency  
    *Annette Bar-Cohen, MA, MPH*
  • Overcoming the Barriers of Transparency  
    *David M. Dilts, PhD, MBA*
  • Panel Question and Answer

**Session Title:** Genetic Predisposition to Survival and Survivorship: How Far Are We from Individualized Therapy?  
**Session Type:** Education Session  
**Track:** Pediatric Oncology  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S504  
  • Genetic Polymorphisms and Translation to Individualized Care: Drug Dosing and Supportive Care  
    *Mark J. Ratain, MD*
  • Impact of Genetic and Molecular Discoveries on Frontline Trials for Treatment of Central Nervous System Tumors  
    *Yoon-Jae Cho, MD*
• Potential for Prevention of Late Effects through Genetic Discovery
  
  *Smita Bhatia, MD, MPH - Chair*
  
• Panel Question and Answer

**Session Title:** Overdiagnosis and Overtreatment in Cancer: Point/Counterpoint

**Session Type:** Education Session

**Track:** Health Services Research

**Time:** 8:00 AM - 9:15 AM

**Location:** E253

• The Case against Overdiagnosis and Overtreatment of Cancer
  
  *Rinaa S. Punglia, MD, MPH*

• Cancer Overdiagnosis and Overtreatment, or Appropriate Attention to Early Disease?
  
  *Barbara L. Smith, MD, PhD - Chair*

• The Case for Overdiagnosis and Overtreatment of Cancer
  
  *Laura Esserman, MD, MBA*

• Panel Question and Answer

**Session Title:** Treatment of the Patient with High-Risk Myeloma - Ticketed Session

**Session Type:** Meet the Professor Session

**Track:** Lymphoma and Plasma Cell Disorders

**Time:** 8:00 AM - 9:15 AM

**Location:** E451a

• High-Risk Myeloma
  
  *Jesús F. San-Miguel, MD, PhD*

**Session Title:** Navigating Treatment Options in Advanced Neuroendocrine Tumors - Ticketed Session

**Session Type:** Clinical Problems in Oncology Session

**Track:** Gastrointestinal (Noncolorectal) Cancer

**Time:** 8:00 AM - 9:15 AM

**Location:** E451b

• Panel Moderator
  
  *George A. Fisher, MD, PhD - Chair*

• Surgical Oncologist
  
  *Eric H Liu, MD*
• Medical Oncologist
  Marianne E. Pavel, MD
• Medical Oncologist
  Jennifer A. Chan, MD, MPH

Session Title: Finding the Targets in Gynecologic Cancers
Session Type: Clinical Science Symposium
Track: Gynecologic Cancer
Time: 8:00 AM - 9:30 AM
Location: E354a

• Co-Chair
  Stephen A. Cannistra, MD
• Co-Chair
  David R. Spriggs, MD
• Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. (Abstract 5509)
  Boris J. N. Winterhoff
• Identifying Value in Antiangiogenic Targeting
  Elise C. Kohn, MD
• Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. (Abstract 5510)
  Pamela T. Soliman
• Disruption of the Obesity Link in Endometrial Cancer
  Victoria Lin Bae-Jump, MD, PhD
• Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. (Abstract 5511)
  Junzo Hamanishi
• Is Immunotherapy Targeting Relevant in Ovarian Cancer?
  Oliver Dorigo, MD
• Panel Question and Answer

Session Title: Novel Combination Therapies for Melanoma
Session Type: Clinical Science Symposium
Track: Melanoma/Skin Cancers
Time: 8:00 AM - 9:30 AM
Location: E Arie Crown Theater

• Chair
  Adil Daud, MD
• Chair
  Rodabe Navroze Amaria, MD

• Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC) (Abstract 9009a^)
  Michael Robert Migden

• Molecular Biological Basis for Rational Combination Strategies in Melanoma
  Michael A. Davies, MD, PhD

• A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. (Abstract 9009)
  Jeffrey Alan Sosman

• Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAFV600 mutation-positive (+) metastatic melanoma (MM). (Abstract 9010^)
  Keith Flaherty

• COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma (Abstract 9011^)
  Georgina V. Long

• Clinical Impact of Dual Inhibitor Therapy for Melanoma
  Antoni Ribas, MD, PhD

• Panel Question and Answer

Session Title: Central Nervous System Tumors
Session Type: Oral Abstract Session
Track: Central Nervous System Tumors
Time: 8:00 AM - 11:00 AM
Location: E450

• Chair
  Howard Alan Fine, MD

• Chair
  Eric L. Chang, MD

• Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. (Abstract 2000)
  Jan C. Buckner

• Controversy or Consensus: Modern Management of Low-Grade Gliomas
  Martin J. Van Den Bent, MD
Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]). (Abstract 2001^)
  Heidi Phillips

A 6-gene signature for outcome prediction of grade II/III glioma. (Abstract 2002)
  Tim Lautenschlaeger

Impact of Molecular Signatures on Clinical Outcome
  Kenneth D. Aldape, MD

Panel Question and Answer

Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter. (Abstract 2003)
  Wolfgang Wick

  Eudocia Quant Lee

Optimizing Outcomes: Special Populations and Treatment Considerations
  Jennifer Leigh Clarke, MD, MPH

Panel Question and Answer

Panel Discussion

A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. (Abstract 2005)
  Patrick Y. Wen

  Michael Platten

Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab. (Abstract 2007)
  Raymond Yi-kun Huang

Applying the Revised Assessment in Neuro-Oncology (RANO) Criteria to Current Clinical Trials in Neuro-Oncology
  Susan Marina Chang, MD

Panel Question and Answer

Panel Discussion

Session Title: Genitourinary (Prostate) Cancer
Session Type: Oral Abstract Session
Track: Genitourinary Cancer
Time: 8:00 AM - 11:00 AM
Location: N Hall B1
Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). (Abstract 5000)  
*Eleni Efstathiou*

Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5001)  
*Emmanuel S. Antonarakis*

The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. (Abstract 5002)  
*Susan Halabi*

Predicting Resistance and Overall Survival in Castration-Resistant Prostate Cancer  
*Mary-Ellen Taplin, MD*

Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. (Abstract 5003)  
*Xabier Garcia-Albeniz*

Main oncologic endpoints of the TROG 03.04 (RADAR) Trial for men with locally advanced prostate cancer (Abstract 5004)  
*James William Denham*

Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial. (Abstract 5005)  
*Karim Fizazi*

Overcoming Barriers in High-Risk, Localized Prostate Cancer  
*Bertrand F. Tombal, MD, PhD*

SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. (Abstract 5006)  
*Evan Y. Yu*

Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial) (Abstract 5008)  
*Ronald De Wit*
• Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). (Abstract 5007)
  Andrew J. Armstrong
• Prolonging Survival in Prostate Cancer: From Hormone Sensitive to Castration Resistant and Beyond
  Scott T. Tagawa, MD
• Panel Question and Answer
  Panel Discussion

**Session Title:** Lymphoma

**Session Type:** Oral Abstract Session

**Track:** Lymphoma and Plasma Cell Disorders

**Time:** 8:00 AM - 11:00 AM

Location: E Hall D2

• Co-Chair
  Jonathon Brett Cohen, MD

• Chair
  Ash A. Alizadeh, MD, PhD

• Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT). (Abstract 8500)
  Franco Cavalli

• Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL. (Abstract 8501)
  Michael Pfreundschuh

• Optimizing Existing Lymphoma Therapies
  Michael E. Williams, MD

• Panel Question and Answer

• Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies. (Abstract 8502)
  Judith Trotman

• Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL). (Abstract 8503)
  Rene-Olivier Casasnovas

• Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. (Abstract 8504)
  David Matthew Kurtz
• Value and Utility in Monitoring Lymphoma Therapies
  *Christopher Flowers, MD*

• Panel Question and Answer
  
  *Panel Discussion*

• Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). (Abstract 8505)
  *Andres Forero-Torres*

• Starlyte phase II study of coltuximab raptansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887). (Abstract 8506)
  *Marek Trneny*

• A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report. (Abstract 8507)
  *Massimo Federico*

• Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. (Abstract 8508)
  *Filip Janku*

• Advances in Therapy of Hodgkin Disease
  *Anas Younes, MD*

• Panel Question and Answer
  
  *Panel Discussion*

---

**Session Title:** Sarcoma  
**Session Type:** Oral Abstract Session  
**Track:** Sarcoma  
**Time:** 8:00 AM - 11:00 AM  
**Location:** S406

• Chair  
  *Hussein Abdul-Hassan Tawbi, MD, PhD*

• Chair  
  *Roberta Sanfilippo, MD*

• Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin—A GEIS study. (Abstract 10500)
  *Javier Martin Broto*

• ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS). (Abstract 10501)
  *Nicolas Penel*

• Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus
doxorubicin in patients with advanced soft tissue sarcomas. (Abstract 10502)

Sant P. Chawla

• Insight and Pitfalls in Randomized Phase II Studies in Sarcomas
  Suzanne George, MD

• Panel Question and Answer

• A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS). (Abstract 10503^)
  William D. Tap

• Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS). (Abstract 10504^)
  Philippe Alexandre Cassier

• Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials. (Abstract 10505)
  Keith M. Skubitz

• Targeted Therapeutics in Orthopedic Sarcomas
  R. Lor Randall, MD

• Panel Question and Answer
  Panel Discussion

• A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report. (Abstract 10506)
  Michael C. Heinrich

• Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST). (Abstract 10507)
  Margaret von Mehren

• Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. (Abstract 10508)
  George D. Demetri

• GIST Trials: Revisiting the Old and Looking Forward to the New
  Jonathan C. Trent, MD, PhD

• Panel Question and Answer
  Panel Discussion
**Session Title:** Breast Cancer - HER2/ER  
**Session Type:** Poster Highlights Session  
**Track:** Breast Cancer  
**Time:** 8:00 AM - 12:45 PM  
Display and Networking Time: 8:00 AM - 11:00 AM  
Display and Networking Location: E354b  
Discussion Time: 11:30 AM - 12:45 PM  
Discussion Location: E Arie Crown Theater

- **Co-Chair**  
  *Tufia C. Haddad, MD*  
- **Co-Chair**  
  *Patrick Glyn Morris, MD, MSc*

**Board 1**  
Obesity and menopausal status as determinants of procarcinogenic breast inflammation. (Abstract 512)  
*Neil M. Iyengar*  
Board 2

**Board 2**  
Association between visceral adiposity, BMI, and clinical outcomes in postmenopausal women with operable breast cancer. (Abstract 513)  
*Shalini Dalal*  
Board 3

**Board 3**  
Impact of insulin resistance (IR) on the prognosis of metastatic breast cancer (MBC) patients treated with first-line chemotherapy (CT). (Abstract 514)  
*Alessandra Gennari*  
Board 4

**Board 4**  
Inhibition of polo-like kinase 1 (PLK1) in endocrine-resistant ER+ breast cancer. (Abstract 515)  
*Valerie Malyvanh Jansen*  
Board 5

**Board 5**  
SU2C phase Ib study of the PI3Ka inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC). (Abstract 516^)  
*Ingrid A. Mayer*  
Board 6

**Board 6**  
Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3Ka–inhibitor plus letrozole (L) or exemestane (E). (Abstract 517)  
*Mary Ellen Moynahan*
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial. (Abstract 518)
Christoph Rochlitz

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC). (Abstract 519)
Joyce O'Shaughnessy

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI). (Abstract 520)
Weimin Li

Rachel Jorge Dino Cossetti

Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC). (Abstract 522)
Ines Maria Vaz Duarte Luis

Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact. (Abstract 523)
Mithun Vinod Shah

Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial. (Abstract 524^)
Oleg Gluz

Prognostic score for Luminal A-like breast cancer patients. (Abstract 525)
Caterina Fontanella

Phase II study of 3'-deoxy-3'-18F fluorothymidine PET/CT (FLT-PET) in the assessment of early response in locally advanced breast cancer (LABC): Preliminary results of ACRIN 6688. (Abstract 526)
Lale Kostakoglu  
Board 17  
• A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. (Abstract 527)  

Amy Sanders Clark  
Board 18  
• TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM). (Abstract 528)  

Rachel A. Freedman  
Board 19  
• Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam). (Abstract 529)  

John F. Forbes  
Board 20  
• An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer. (Abstract 530)  

Giampaolo Bianchini  
Board 21  
• Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC). (Abstract 531)  

Antoinette R. Tan  
Board 22  
• Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR+ early-stage breast cancer: A TransATAC study. (Abstract 532)  

Ivana Sestak  
Board 23  
• Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2- BC). (Abstract 533)  

Pamela N. Munster  
Board 24  
• LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. (Abstract 534)  

Amita Patnaik  
Board 25  
• Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2- metastatic breast cancer. (Abstract 535)  

Aditya Bardia  
Board 26  
• Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. (Abstract 536)
Nikhil Wagle
- Obesity Matters: A Call to Action
  Jennifer A. Ligibel, MD
- Overcoming the Hurdle of Endocrine Resistance in Breast Cancer
  Bryan Hennessy, MD
- Targeted Therapies in ER+ Breast Cancer: New Horizons
  Tiffany A. Traina, MD
- Risk Stratification and Treatment Selection in Early-Stage ER+ Breast Cancer
  Laura van't Veer, PhD
- Panel Question and Answer

Session Title: Gastrointestinal (Noncolorectal) Cancer
Session Type: Poster Highlights Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 8:00 AM - 12:45 PM
Display and Networking Time: 8:00 AM - 11:00 AM
Display and Networking Location: E354b
Discussion Time: 11:30 AM - 12:45 PM
Discussion Location: E Hall D2
- Co-Chair
  Syma Iqbal, MD
- Co-Chair
  Geoffrey Yuyat Ku, MD, MBA
  Board 27
- A randomized phase III study in advanced esophageal cancer (OC) to compare the quality of life (QoL) and palliation of dysphagia in patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2. (Abstract 4009)
  Michael Gordon Penniment
  Board 28
- Can induction chemotherapy improve dysphagia in locally advanced esophageal/GEJ cancer? (Abstract 4010)
  Elizabeth Won
  Board 29
  Aslam Ejaz
• Lymph node yield and survival in gastric carcinoma. (Abstract 4012)
  
  Jennifer E. Samples

• Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK 02/010). (Abstract 4014)
  
  David Cunningham

• Association of a DNA damage response deficiency (DDRD) assay and prognosis in early-stage esophageal adenocarcinoma. (Abstract 4015)
  
  Richard C. Turkington

• Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG). (Abstract 4016)
  
  Russell D. Petty

• Tumor profiling of 1,306 gastric and esophageal carcinomas and different treatment options. (Abstract 4017)
  
  John Thomas Miura

• Genetic variants in tumor immune checkpoints as prognostic markers in patients (pts) with localized advanced gastric cancer (AGC). (Abstract 4018)
  
  Yu Sunakawa

• Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial. (Abstract 4019)
  
  Shukui Qin

• E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. (Abstract 4020)
  
  Steven J. Cohen

• A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer. (Abstract 4021)
  
  Johanna Wilmink
Board 41

- PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). (Abstract 4022)
  
  *Sharlene Gill*

Board 42

- Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). (Abstract 4023)
  
  *Eileen Mary O'Reilly*

Board 43

- Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial. (Abstract 4024)
  
  *Dewi Vernerey*

Board 44

- Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. (Abstract 4025)
  
  *Jean-Luc Van Laethem*

Board 45

- Feasibility and results of a randomized phase IIb study of fractionated 90°-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. (Abstract 4026)
  
  *Vincent J. Picozzi*

Board 46

- Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC). (Abstract 4027^)
  
  *David Goldstein*

Board 47

- Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial. (Abstract 4028^)
  
  *Andrew X. Zhu*

Board 48

- Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC). (Abstract 4029)
  
  *Tudor-Eliade Ciuleanu*
• SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA). (Abstract 4030)
  Edgar Ben-Josef
  Board 50

• A comparison between 5-fluorouracil/mitomycin (FM) and capecitabine/mitomycin (CM) in combination with radiation (RT) for squamous cell carcinoma (SCC) of the anal canal. (Abstract 4031)
  Dante D.C. Wan
  Board 51

• Patient and tumor characteristics impacting on lymph node metastases rate (LNMR) in squamous cell carcinoma of the anal canal and margin (SCCA) using data from the NCRI randomized phase III ACT II trial: Implications for radiotherapy target volume. (Abstract 4032)
  Robert Glynne-Jones
  Board 52

• Nomograms to predict prognosis in pseudomyxoma peritonei: A Peritoneal Surface Oncology Group International (PSOGI) multicenter study. (Abstract 4033)
  Shigeki Kusamura

• Contemporary Management of Esophagogastric Cancer
  Florian Lordick, MD PhD

• Biologic Horizons in Esophagogastric Cancer
  Wafik S. El-Deiry, MD, PhD

• Novel Targets, Novel Markers in Pancreatobiliary and Hepatic Cancers
  Anthony B. El-Khoueiry, MD

• Chemoradiation Trials in Noncolorectal Gastrointestinal Cancer
  Lisa A. Kachnic, MD

• Panel Question and Answer

Session Title: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Session Type: Poster Highlights Session
Track: Lung Cancer
Time: 8:00 AM - 12:45 PM
Display and Networking Time: 8:00 AM - 11:00 AM
Display and Networking Location: S405
Discussion Time: 11:30 AM - 12:45 PM
Discussion Location: S406
• Co-Chair
  Anne C. Chiang, MD, PhD
• Co-Chair

David Ball, MBBS, MD, FRANZCR

Board 1

• A randomized trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA N2 non-small cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. (Abstract 7508)

Si-Yu Wang

Board 2

• Postoperative radiotherapy (PORT) for pathologic N2 non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: A review of the National Cancer Database. (Abstract 7509)

Cliff Grant Robinson

Board 3

• Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIib (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE). (Abstract 7510)

Wilfried Ernst Erich Eberhardt

Board 4

• Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial. (Abstract 7511^)

Jean Tredaniel

Board 5

• Multidisciplinary treatment for stage IIIA non-small cell lung cancer (NSCLC): Does institution matter? (Abstract 7512)

Pamela Parker Samson

Board 6

• Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial. (Abstract 7513)

Frances A. Shepherd

Board 7

• SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. (Abstract 7514)

Nathan A. Pennell

Board 8

• NEOSCAN: Phase II trial of neoadjuvant chemotherapy for resectable lung cancers with switch to chemo alternative in 18F-FDG PET nonresponders. (Abstract 7515)

Mark G. Kris

Board 9

• Driver mutations associated with smoking and other environmental factors: Prospective and
integrative genomic analysis from the Japan Molecular epidemiology for Lung Cancer Study (JME). (Abstract 7516)

Norimasa Ito
Board 10

• PD-L1 expression and genotype in non-small cell lung cancer (NSCLC). (Abstract 7517)

Sascha Ansen
Board 11

• Second primary lung cancers: Analysis of E5597 selenium chemoprevention study. (Abstract 7518)

Rathi Narayana Pillai
Board 12

• Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum. (Abstract 7519)

Morten Mau-Soerensen
Board 13

• Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC). (Abstract 7520)

Atsushi Nakamura
Board 14

• Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901. (Abstract 7521)

Yosuke Kawashima
Board 15

• Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. (Abstract 7522)

Zev A. Wainberg
Board 16

• A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: An Eastern Cooperative Oncology Group study (E2511). (Abstract 7523)

Taofeek Kunle Owonikoko
Board 17

• Analysis of small cell lung cancer (SCLC) patients (Pts) treated on cancer therapy evaluation program (CTEP)-sponsored phase I trials: 1992-2012. (Abstract 7524)

Patrick M. Forde
Board 18

• Phase II trial of sunitinib in patients with thymic epithelial tumors (TET). (Abstract 7525)

Anish Thomas
• A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). (Abstract 7526)
  Benjamin Besse

• Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. (Abstract 7527)
  Paolo A. Zucali

• Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial. (Abstract 7528)
  Carlo Buonerba

• Recurrence of epigenetic gene mutations in thymic epithelial carcinomas revealed by targeted exome sequencing of cancer-associated genes. (Abstract 7529)
  Yisong Wang

• Next-generation sequencing in malignant pleural mesothelioma: A retrospective study. (Abstract 7530)
  Giorgio V. Scagliotti

• A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. (Abstract 7531)
  Luana Calabrò

• Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM). (Abstract 7532)
  Raffit Hassan

• Multimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer
  Feng Ming Kong, MD, PhD

• EGFR and Beyond in Early-Stage Non-Small Cell Lung Cancer
  Tony Mok, MD

• Small Cell Lung Cancer: The Future Awaits
  Tom John, MBBS, PhD, FRACP

• Moving Beyond Chemotherapy in Thymic Malignancies and Mesothelioma
  Gregory J. Riely, MD, PhD

• Panel Question and Answer
Session Title: Cancer Prevention/Epidemiology
Session Type: General Poster Session
Track: Cancer Prevention/Epidemiology
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

- Genetic variant in the microRNA binding site of $DOK3$ (rs2279398G>A) and susceptibility to colorectal cancer. (Abstract 1537)
  Jong Gwang Kim
  Board 319

- Analysis of somatic copy number alterations in pediatric solid tumors using array comparative genomic hybridization. (Abstract 1538)
  Alanna Church
  Board 321

- Argentinean Jewish population frequencies for common mutations in BRCA1, BRCA2, and CHEK2. (Abstract 1539)
  Paola Jablonski
  Board 322

- Using next-generation sequencing (NGS) to identify causative mutations in Asian cancer (CA) patients with suspected Lynch syndrome. (Abstract 1540)
  Samuel Guan Wei Ow
  Board 323

  Jamie Willmott
  Board 324

- Analysis of patients with two hereditary cancers (breast/ovarian or colon/endometrial) who met NCCN genetic testing criteria after their first cancer. (Abstract 1542)
  Jennifer Saam
  Board 325

- Predictors of weight gain in breast cancer survivors. (Abstract 1543)
  Iram Tauqeer Azam
  Board 327

- Effect of reproductive factors and lifestyle on the onset of breast cancer in female BRCA 1 and 2 mutation carriers. (Abstract 1545)
  Christian F. Singer
• How are young women 18-24 counseled on hereditary breast and ovarian cancer (HBOC) testing? (Abstract 1546)
  Amy Abramowitz

• The landscape of precision medicine cancer clinical trials in the United States. (Abstract 1547)
  Nitin Roper

• The clinical experience: Hereditary cancer testing by a 25-gene panel. (Abstract 1548)
  Elias Obeid

• Implications of following the guidelines for genetic testing and MRI use for breast cancer. (Abstract 1549)
  Fernanda C. G. Polubriaginof

• Genetic anticipation in BRCA1/2 families after controlling for ascertainment bias and cohort effect. (Abstract 1550)
  Rodrigo Santa Cruz Guindalini

• Are immunohistochemical (IHC)/microsatellite instability (MSI) testing necessary as part of Lynch syndrome work-up in the era of multiplex genetic testing? (Abstract 1551)
  Ahmad Fitri Idris

• Impact of an interventional counseling procedure in BRCA families: Efficacy and safety. (Abstract 1552)
  Erica Sermijn

• Impact of 25-gene panel testing and integrated risk management tool on medical management in hereditary cancer syndrome evaluation. (Abstract 1553)
  Lucy R. Langer

• Shortened telomere length to predict initiation of carcinogenesis in Lynch syndrome. (Abstract 1554)
  Grainne O’Kane

• Classification of somatic variants in solid tumors detected by next-generation sequencing (NGS) and the need for clinical guidelines. (Abstract 1555)
  Antonios Papanicolau-Sengos
• The clinicopathologic significance of FOXC1 in \textit{BRCA}-mutant breast cancer. (Abstract 1556)
  \textit{Michael Phillip Choi}

• Familial clustering and predisposition to HPV-associated malignancy. (Abstract 1557)
  \textit{Judith Conroy}

• Association of the \textit{HOXB13 G84E} mutation with increased risk for prostate cancer and other malignancies. (Abstract 1558)
  \textit{Jennifer Beebe-Dimmer}

• BRCAPRO 6.0 model validation in male patients presenting for \textit{BRCA} testing. (Abstract 1559)
  \textit{Zahi Ibrahim Mitri}

• Women from certain \textit{BRCA1/2}-mutation–negative hereditary breast ovarian cancer families and consideration of prophylactic salpingo-oophorectomy before menopause. (Abstract 1560)
  \textit{Nataliya Rozumna-Martynyuk}

• Biologic pathways, candidate genes, and molecular markers associated with quality-of-life domains. (Abstract 1561)
  \textit{Jeff A. Sloan}

• Analysis of global gene expression in adrenocortical tumors from Li-Fraumeni syndrome \textit{TP53} germline mutation carriers. (Abstract 1562)
  \textit{Fernanda Fortes}

• Single nucleotide polymorphisms and smoking status for prediction of non-small cell lung cancer. (Abstract 1563)
  \textit{Junjie Wu}

• Contribution of extended family history in assessment of risk for breast and colon cancer. (Abstract 1564)
  \textit{Benjamin Lev Solomon}

• Cost-effectiveness of aromatase inhibitors versus selective estrogen-receptor modulators for breast cancer prevention in postmenopausal women. (Abstract 1565)
  \textit{Amy Grace Groom}
- Low-dose CT lung cancer screening in the community: A prospective cohort study. (Abstract 1566)
  Vincent K. Lam
  Board 349
- A population-based comparison of outcomes among screening, symptom, and emergently-detected colorectal cancer (CRC). (Abstract 1567)
  McKyla McIntyre
  Board 350
- Correlation between risk benefit index and uptake of breast cancer chemoprevention. (Abstract 1568)
  Parijatham S. Sivasubramanian
  Board 351
- Characteristics of HIV+ lung cancer cases in a large clinical population: Implications for lung cancer screening. (Abstract 1569)
  Marina Shcherba
  Board 352
- Randomized trials on mammography screening and the left-to-nature design. (Abstract 1570)
  Philippe Autier
  Board 353
- One hundred years of cancer mortality in Scotland (1911-2010). (Abstract 1571)
  Peter Boyle
  Board 354
- A population-based analysis of the impact of physicians on cancer screening. (Abstract 1572)
  Leo Chen
  Board 355
- Risk-reducing salpingectomy at the time of benign gynecologic surgery: A survey of ACOG members in New York State. (Abstract 1573)
  Joshua Stewart
  Board 356
- Vulnerable populations and overconfidence in cancer screening. (Abstract 1574)
  François Eisinger
  Board 357
- Prevalence of smoking in cancer survivors: National Health and Nutrition Examination Survey (NHANES) III data analysis. (Abstract 1575)
  Mohammed Shaik
  Board 358
- Breast cancer incidence among young women of urban China (Shanghai) and in Canada: Implications for prevention. (Abstract 1576)
Joseph Ragaz
Board 359
• Cancer screening behaviors among spouses in a nationally representative sample. (Abstract 1577)

Ashwin A Kotwal
Board 360
• Identifying barriers to providing tobacco cessation support for cancer patients. (Abstract 1578)

James Roger Marshall
Board 361
• Cervical cancer screening: Twelve years experience with high-risk population of southern Mexico. (Abstract 1579)

Francisco Gutierrez-Delgado
Board 362
• The effect of current smoking on mortality in cancer patients. (Abstract 1580)

Graham Walter Warren
Board 363
• Pioglitazone as a candidate chemoprevention agent for lung cancer: A pilot window trial in early stage NSCLC. (Abstract 1581)

Dennis A. Wigle
Board 364
• Lung cancer characteristics in 762 never- and 6,246 ever-smoker patients: Study KBP-2010-CPHG. (Abstract 1582)

Daniel Coëtmeur
Board 365
• Multiple primary malignancies involving primary sporadic colorectal cancer in Japan: Incidence of gastric cancer with colorectal cancer patients may be higher than previously recognized. (Abstract 1583)

Takaharu Kato
Board 366
• A population-based study of incidence and survival trends of 1,261 thymic malignancies (TM): Results from the California Cancer Registry (CCR). (Abstract 1584)

Jonathan Riess
Board 367
• The incidence of testicular cancer in the United States and Europe from 1992 to 2009. (Abstract 1585)

Manas Nigam
Board 368
• Cancer patients’ acceptability of incorporating an epidemiology questionnaire within a clinical trial: A patient preference study and subanalysis of the NCIC clinical trials group HN.6 clinical trial. (Abstract 1586)
  *Sinead Cuffe*
  Board 369

• Rising incidence of young-onset colorectal cancer in Texas, 1995-2010. (Abstract 1587)
  *Daniel Ying Wang*
  Board 370

• Frequency and clinical significance of extramammary findings on breast magnetic resonance imaging. (Abstract 1588)
  *Catherine Elizabeth Moore*
  Board 371

• Age-related change in breast cancer stage at diagnosis relative to increased mammography detection over time: 1990-2012. (Abstract 1589)
  *Judith April Malmgren*
  Board 372

• Multicenter observational study of reactivation of hepatitis B virus (HBV) caused by chemotherapy for solid tumors (ST). (Abstract 1590)
  *Shunsuke Kondo*
  Board 373

• A comparative analysis of the association between health expenditure and cancer survival in 168 countries. (Abstract 1591)
  *Felipe Ades*
  Board 374

• The prevalence of severe vitamin D (vitD) deficiency and its effect on tumour indices and clinical outcomes in patients with early breast cancer (EBC). (Abstract 1592)
  *Kasia M. Owczarczyk*
  Board 375

• Effect of CHRNA9 polymorphisms and passive smoking on the risk of breast cancer in Taiwan. (Abstract 1593)
  *Yi-Chen Hsieh*
  Board 376

• The risk of second primary malignancy among male breast cancer patients: A population-based study. (Abstract 1594)
  *Man-Hsin Hung*
  Board 377

• A nomogram associated with high probability of invasive carcinoma on the surgical specimen in patients with preoperative diagnosis of ductal carcinoma in situ of the breast. (Abstract 1595)
  *Takafumi Kondo*
• Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region. (Abstract 1596)
  
  Jeovany Martínez-Mesa

• Obesity-induced alteration in iron metabolism via elevated hepcidin and the risk of postmenopausal breast cancer among Caucasians. (Abstract 1597)
  
  Puja Agarwal

• Incidence trends of keratinocytic skin cancers and melanoma in Israel 2006-2011. (Abstract 1598)
  
  Tal Sella

• Impact of antibiotic exposure on the risk of colorectal cancer. (Abstract 1599)
  
  Shimon Ben Boursi

• Thyroid hormone replacement and the risk for colorectal cancer. (Abstract 1600)
  
  Shimon Ben Boursi

• Long-term breast cancer outcomes in Canada with special analyses of cancer care access and mortality reduction. (Abstract 1601)
  
  Joseph Ragaz

• Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain. (Abstract 1602)
  
  Marina Pollán

• Importance of durational hormone therapy in breast cancer patients in Germany: Retrospective database analysis. (Abstract 1603)
  
  Nina Schmidt

• Association of diabetes and cancer-diagnoses in primary care practices in Germany. (Abstract 1604)
  
  Nina Schmidt

• Incidence of cardiovascular events in the real-world population of cancer patients treated with targeted therapies. (Abstract 1605)
  
  Jonathan G Zaroff
• Gender disparity in breast cancer: A veteran population-based comparison. (Abstract 1606)
  Anita Aggarwal
  Board 389

  Erin Dunn
  Board 390

• The decrease in global cancer mortality. (Abstract 1608)
  Paolo Boffetta
  Board 391

• Prevalence of COPD in a lung cancer case-control study: Variability by assessment method and by race. (Abstract 1609)
  Ann G. Schwartz
  Board 392

• Statins and survival in a cohort of veterans with chronic lymphocytic leukemia (CLL). (Abstract 1610)
  Abdullah Mohammad Khan
  Board 393

• Comparison of false-negative probabilities for digital and film mammography within a large health care organization. (Abstract 1611)
  Firas M Dabbous
  Board 394

• Is digital mammography associated with a higher risk of false-positive results? Findings from a community setting. (Abstract 1612)
  Firas M Dabbous
  Board 395

• Gastric cancer: Clinical differences among Hispanic and non-Hispanic whites at the John Theurer Cancer Center (JTCC), Hackensack University Medical Center. (Abstract 1613)
  Narjust Perez-Florez
  Board 396

• Ethnic disparities in pediatric Ewing sarcoma and osteosarcoma. (Abstract 1614)
  Adam L. Green
  Board 397A

• A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease. (Abstract TPS1615)
  Ayca Gucalp
  Board 397B

• MELO-D: Antiproliferative effects of melatonin and vitamin D in breast cancer. (Abstract TPS1616)
Punam Rana  
Board 398A

• Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors. (Abstract TPS1617)

Ruth E Langley  
Board 398B

• Community-based cluster randomized trial of screening with visual examination of oral cavity and double-contrast barium swallow for upper aerodigestive tract cancers. (Abstract TPS1618)

Conjeevaram S Pramesh

Session Title: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics  
Session Type: General Poster Session  
Track: Developmental Therapeutics  
Time: 8:00 AM - 11:45 AM  
Location: S Hall A2

Board 1

• Relationships between occurrence of chills and clinical outcome during NGR-hTNF therapy. (Abstract 2538)  
Alessandra Bulotta

Board 2

• Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. (Abstract 2539)  
Joleen Marie Hubbard

Board 3

• Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort. (Abstract 2540)  
Robin Kate Kelley

Board 4

• Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors. (Abstract 2541)  
Paul Elvin

Board 5

• A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors. (Abstract 2542)  
Afshin Dowlati
Board 6
- A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts). (Abstract 2543)
  *Lipika Goyal*

Board 7
- A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC. (Abstract 2544)
  *Mark James McKeage*

Board 8
- Effect of sulfasalazine (SSZ) on cancer stem-like cells (CSCs) via inhibiting xCT signal pathway: Phase 1 study in patients with gastric cancer (EPOC 1205). (Abstract 2545)
  *Kohei Shitara*

Board 9
- A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors. (Abstract 2546)
  *Derek J. Jonker*

Board 10
- Characterization of isolated, uncomplicated neutropenia–related to the CDK4/6 inhibitor palbociclib. (Abstract 2547)
  *Angela DeMichele*

Board 11
- Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study. (Abstract 2548)
  *Vincent Launay-Vacher*

Board 12
- Correlation between phase 2 clinical trial design and subsequent phase 3 outcome. (Abstract 2549)
  *Annette E. Hay*

Board 13
- Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors. (Abstract 2550^)
  *Pierre Fumoleau*

Board 14
- Pharmacodynamic assay for evaluation of first-in-class pyruvate kinase-M2 activators in tumors. (Abstract 2551)
  *Payal Khanna*

Board 15
- Risks and benefits of phase 1 oncology trials, 2001 through 2012. (Abstract 2552)
  *Yoko Korenaga Fukuda*
• Integrated nonclinical and clinical risk assessment to obviate the need for a dedicated QTc study of ixazomib citrate (MLN9708) in cancer patients (pts). (Abstract 2553)
  
  Neeraj Gupta

• First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors. (Abstract 2554)
  
  Rajiv Kumar

• A phase I study of ARQ 197 in combination with temsirolimus in patients (Pts) with advanced solid tumors. (Abstract 2555)
  
  Amy M. Braden

• Predicting success in regulatory approval from phase I results. (Abstract 2556)
  
  Laeeq Malik

• A phase 1 study of phospholipid ether [131I]-CLR1404 in patients with advanced solid tumors. (Abstract 2557)
  
  Sam Joseph Lubner

• A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL). (Abstract 2558)
  
  Taofeek Kunle Owonikoko

• Population pharmacokinetics (PK) and exposure–neutropenia relationship of nab-paclitaxel (nab-P) in patients (pts) with solid tumors. (Abstract 2559)
  
  Nianhang Chen

• A phase I study of metformin and chemotherapy in solid tumors. (Abstract 2560)
  
  Athena Kritharis

• Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. (Abstract 2561)
  
  Ami P. Jhaveri

• Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed. (Abstract 2562)
  
  L Rhoda Molife
• Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin. (Abstract 2563)
  
  Siqing Fu  
  Board 27

• First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein. (Abstract 2564)
  
  Klaus B. Mross  
  Board 28

• Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy. (Abstract 2565)
  
  Charles Ferte  
  Board 29

• A phase I and pharmacokinetic study of a weekly dosing schedule of paclitaxel injection concentrate for nano-dispersion (PICN) in patients with advanced solid tumors. (Abstract 2566)
  
  Wen Wee Ma  
  Board 30

• A phase I study of pemetrexed in combination with docetaxel in advanced solid tumor patients. (Abstract 2567)
  
  Lee D. Cranmer  
  Board 31

• Aurora-A mitotic kinase and induction of endocrine resistance through downregulation of era expression in initially era+ breast cancer cells. (Abstract 2568)
  
  Mateusz Opyrchal  
  Board 32

• Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer. (Abstract 2569)
  
  Eve T. Rodler  
  Board 33

• Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). (Abstract 2570)
  
  Shannon Puhalla  
  Board 34

• Intraoral JP4-039 to ameliorate irradiation-induced mucositis in tumor-bearing Fanconi anemia (FA) mouse model. (Abstract 2571)
  
  Ashwin Shinde  
  Board 35
• Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG). (Abstract 2572)
  Hussein Abdul-Hassan Tawbi
  Board 36

• Phase 1/2 study of oral rucaparib: Final phase 1 results. (Abstract 2573)
  Rebecca Sophie Kristeleit
  Board 37

• A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors. (Abstract 2574)
  Jordan Berlin
  Board 38

• Phase I dose-escalation study of an oral administration of the pan-histone deacetylase inhibitor abexinostat combined with a fixed dose of doxorubicin in patients with solid tumors. (Abstract 2575)
  Arnaud Scherpereel
  Board 39

• A phase 1 trial of pazopanib and vorinostat: The role of TP53 mutations. (Abstract 2576)
  Ming-Mou Hou
  Board 40

• Phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (Pts) with metastatic solid tumors. (Abstract 2577)
  Rahul Raj Aggarwal
  Board 41

• A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent. (Abstract 2578)
  Tony R. Reid
  Board 42

• Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. (Abstract 2579)
  Yutaka Fujiwara
  Board 43

• A presurgical study of oral silybin-phosphatidylcholine in patients with early breast cancer. (Abstract 2580)
  Matteo Lazzeroni
  Board 44

• Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors. (Abstract 2581)
  Ding Wang
• Analysis of impact of post-treatment biopsies in phase I clinical trials. (Abstract 2582)
  Randy F. Sweis

Board 46
• Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors: A UNICANCER phase I study. (Abstract 2583)
  Veronique Dieras

Board 47
• Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors. (Abstract 2584)
  Jennifer Robinson Diamond

Board 48
• Clinical pharmacokinetic (PK)/pharmacodynamic (PD) model for Debio 1143, a novel antagonist of IAPs in cancer treatment. (Abstract 2585)
  Elisabeth Rouits

Board 49
• Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma. (Abstract 2586)
  Wael Harb

Board 50
• Population pharmacokinetic (PK) analysis from phase 1 and 2 studies of the HER3 inhibitor patritumab in patients with advanced non-small cell lung cancer (NSCLC) or solid tumors. (Abstract 2587)
  Satoshi Yoshiba

Board 51
• A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer. (Abstract 2588)
  Ramesh K. Ramanathan

Board 52
• Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status. (Abstract 2589)
  Jun Zhang

Board 53
• Tyrosine kinase inhibitors and QTc intervals: A class effect. (Abstract 2590)
  Jacqueline S.L. Kloth

Board 54
• Cytochrome P450 interacting medication use in adult advanced solid tumor and phase I trial patients. (Abstract 2591)
  Kari Braun Wisinski
• The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. (Abstract 2592)
  Feng Jin
  Board 56

• Drug interaction profile of idelalisib and its major metabolite, GS-563117. (Abstract 2593)
  Feng Jin
  Board 57

• The impact of gastric acid suppression therapy on tyrosine kinase inhibitors in advanced cancer patients. (Abstract 2594)
  Michael Patvin Chu
  Board 58

• Pharmacokinetics (PK) of eribulin mesylate in cancer patients (pts) with normal and impaired renal function. (Abstract 2595)
  Antoinette R. Tan
  Board 59

• Choice of starting dose for biopharmaceuticals in first-in-human phase I cancer clinical trials. (Abstract 2596)
  Aaron Richard Hansen
  Board 60

• Effect of toxicity-adjusted dose (TAD) of sunitinib on intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer (mRCC). (Abstract 2597)
  Alison Yan Zhang
  Board 61

• Comparison of chemosensitivity testing of CETCs and spheroids in cancer patients with solid tumors. (Abstract 2598)
  Katharina Pachmann
  Board 62

• Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation. (Abstract 2599)
  Ignace Vergote
  Board 63

• Evaluation of the potential for QT/QTc interval prolongation for therapeutic biotechnology products. (Abstract 2600)
  Sarah J Schrieber
  Board 64

• Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors. (Abstract 2601)
  Sarina Anne Piha-Paul
Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors. (Abstract 2602)

David Fairman

A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors. (Abstract 2603)

Gerald J. Fetterly

Risk of serious infection with mTOR inhibitors everolimus and temsirolimus in the treatment of cancer: A meta-analysis of randomized controlled trials. (Abstract 2604)

Christine Ann Garcia

Phase I trial of daily PI3Ka inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). (Abstract 2605)

Payal Deepak Shah

PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. (Abstract 2606)

Jennifer J. Wheler

TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. (Abstract 2607)

Desamparados Roda

A study of risk of infection with drugs targeting the PI3 kinase (PI3K), AKT, and mTOR pathway. (Abstract 2608)

Saeed Rafii

Correlation of intratumoral metabolic changes measured with 18F-FDG PET parametric response maps with concentrations of CC-223, a TORC 1/2 kinase inhibitor, in human glioblastoma. (Abstract 2609)

Benjamin M. Ellingson

Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients. (Abstract 2610)

Richard D. Kim
• Analysis of inactivation of PI3K/AKT/mTOR signaling pathway using neoadjuvant BKM120 in PI3KCA mutated early breast cancer. (Abstract 2611)
  Estevez G Laura
  Board 75
• Complications of hyperglycemia in phase 1 trials targeting the PI3K-akt-mTOR (PAM) pathway. (Abstract 2612)
  Elena Geuna
  Board 77
• Phase 1 study of combination carboplatin, paclitaxel, and ridaforolimus in patients with solid, endometrial, and ovarian cancers. (Abstract 2614)
  Hye Sook Chon
  Board 78
• First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors. (Abstract 2615)
  Jian-Ming Xu
  Board 79
• A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced hepatocellular carcinoma (HCC). (Abstract 2616)
  Masafumi Ikeda
  Board 80
• A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers. (Abstract 2617)
  Chia-Chi Lin
  Board 81
• Heregulin expression level as a predictive biomarker for patritumab efficacy. (Abstract 2618)
  Matthias Schneider
  Board 82
• Pharmacokinetics and pharmacodynamics of the dual syk/jak inhibitor PRT062070 (cerdulatinib) in patients with advanced B-cell malignancies. (Abstract 2619)
  Ian Flinn
  Board 83
• A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer. (Abstract 2620)
  Hendrik-Tobias Arkenau
  Board 84
• Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program. (Abstract 2621)
  Philippe Cassier
• Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors. (Abstract 2622)
  
  *Karim Rihawi*

• Phase I trial of bortezomib daily dose: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors. (Abstract 2623)
  
  *Rastislav Bahleda*

• Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design. (Abstract 2624^)
  
  *Michael L. Maitland*

• MAPK/ERK as a biomarker for cisplatin resistance in squamous cell carcinoma (SCC). (Abstract 2625)
  
  *Li Ren Kong*

• Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients’ avatars. (Abstract 2626)
  
  *Alberto Bardelli*

• A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study. (Abstract 2627)
  
  *James I. Geller*

• A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in *BRAF*-mutated advanced malignancies. (Abstract TPS2628)
  
  *Sigurdis Haraldsdottir*

• First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors. (Abstract TPS2629^)
  
  *Martin Henner Voss*

• A phase 1 dose-escalation study of EC1456, a folic acid-tubulysin small-molecule drug conjugate, in adult patients (pts) with advanced solid tumors. (Abstract TPS2630)
  
  *Wael A. Harb*

• Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors. (Abstract TPS2631^)
Chia-Chi Lin
Board 93A
• The HALO study: A phase I-II of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC. (Abstract TPS2632)

Jesus Corral Jaime
Board 93B
• Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process. (Abstract TPS2633)

Meredith B. Buxton
Board 94A
• Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients. (Abstract TPS2634)

Daigo Yamamoto
Board 94B
• Phase I study of IGF-methotrexate conjugate in the treatment of refractory malignancies expressing IGF-1R. (Abstract TPS2635)

Rozina A. Chowdhery
Board 95A
• A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel. (Abstract TPS2636)

Vincent M. Chung
Board 95B
• Phase I/IB trial of eribulin and everolimus in patients with triple-negative metastatic breast cancer. (Abstract TPS2637)

Thehang H. Luu
Board 96A
• A phase II study of sirolimus and erlotinib in recurrent/refractory germ cell tumors. (Abstract TPS2638)

Theodore Willis Laetsch
Board 96B
• A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. (Abstract TPS2639)

Manojkumar Bupathi
Board 97A
• A phase I trial of MK-2206 and hydroxychloroquine(HCQ) in solid tumors, melanoma, renal, and prostate cancer to examine the role of autophagy in tumorigenesis. (Abstract TPS2640)

Amanda D. Kaveney
Board 97B
• A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer. (Abstract TPS2641)
  Akash Patnaik
  Board 98A

• NCI mpact: National Cancer Institute molecular profiling-based assignment of cancer therapy. (Abstract TPS2642)
  Shivaani Kummar
  Board 98B

• A randomized, parallel-dose phase 1 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers. (Abstract TPS2643)
  Paul H. Cottu
  Board 99A

• Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies. (Abstract TPS2644)
  Kian-Huat Lim
  Board 99B

• BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. (Abstract TPS2645^)
  Matthias Scheffler
  Board 100A

• The signature program, a series of tissue-agnostic, mutation-specific signal finding trials. (Abstract TPS2646^)
  Eric Daniel Slosberg
  Board 100B

• Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National Acsé Program. (Abstract TPS2647)
  Gilles Vassal

**Session Title:** Developmental Therapeutics - Immunotherapy

**Session Type:** General Poster Session

**Track:** Developmental Therapeutics

**Time:** 8:00 AM - 11:45 AM

Location: S Hall A2
  Board 101

• Dose-seeking phase I trials (DSP1T) for currently approved molecular-targeted therapies (MTT): We are still far from using appropriate designs. (Abstract 3034)
  Nuria Kotecki
• Cancer patients (pts) being replaced in dose-seeking phase I trials (DSP1T): Occurrence, outcome, and risk factors. (Abstract 3035)
  *Sophie Cousin*

• Cancer genomics-based approach for development of new immunotherapeutics for lung cancers. (Abstract 3036)
  *Yataro Daigo*

• Prognostic significance of the neutrophil-lymphocyte ratio (NLR) in phase 1 clinical trial patients. (Abstract 3037)
  *Rajiv Kumar*

• Biomarkers for immunotherapy: Results from the analysis of an HLA-status double-blind, biologically randomized phase II study of five therapeutic epitope-peptides with oxaliplatin-based chemotherapy as first-line therapy for advanced colorectal cancer (FXV study). (Abstract 3038)
  *Shoichi Hazama*

• Tumor cells/leukocytes ratio (TLR) in peritoneal fluids as a biomarker in patients with peritoneal metastasis of gastric cancer. (Abstract 3039)
  *Joji Kitayama*

• Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications). (Abstract 3040)
  *Carlos Bais*

• Predictive markers for clinical outcome after neoadjuvant radiochemotherapy in breast cancer patients. (Abstract 3041)
  *Christiane Matuschek*

• Evaluation of changes on tumor-infiltrating lymphocytes and regulatory T-cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast cancer patients and relation with pathologic complete response. (Abstract 3042)
  *Luis de la Cruz Merino*

• Development of an IHC-based detection method for studying indoleamine 2,3-dioxygenase 1 (IDO1) expression in human cancers. (Abstract 3043)
  *Alton Hiscox*
• Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with lenalidomide in advanced solid tumors: A phase 1 trial. (Abstract 3044)
  Erin Marie Bertino
  Board 112
• Endogenous anti-ß-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients. (Abstract 3045)
  Nandita Bose
  Board 113
• Clinical and pathologic correlation of the activated form of the estrogen receptor beta (ERß) in breast cancer (BC). (Abstract 3046)
  Emilie Hutt
  Board 114
• Expansion of peptide-specific T cells from human melanoma-draining lymph nodes. (Abstract 3047)
  Madeleine Strohl
  Board 115
• Preclinical evaluation of anti-RON antibody-drug maytansinoid conjugates (anti-RON ADC) for targeted colorectal cancer therapy. (Abstract 3048)
  Liang Feng
  Board 116
• A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy. (Abstract 3049)
  Haidong Dong
  Board 117
• Antibody-mediated modulation of the IgM B-cell receptor (BCR) expression and signaling. (Abstract 3050)
  Sydney Welt
  Board 118
• Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. (Abstract 3051)
  Dmitriy Zamarin
  Board 119
• Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts). (Abstract 3052^)
  Amita Patnaik
  Board 120
• Association between immune-checkpoint inhibitor induced tumor shrinkage and overall survival in advanced melanoma and NSCLC. (Abstract 3053)
Yan Feng
Board 121
• Immune escape mechanisms associated with tumor recurrence after adoptive cell transfer immunotherapy. (Abstract 3054)

Marco Donia
Board 122
• Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy. (Abstract 3055)

Nicole Haense
Board 123
• Effect of interferon-a on redirected γδ-cell killing of pancreatic and gastric cancers. (Abstract 3056)

David M. Goldenberg
Board 124
• A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs). (Abstract 3057)

Wei-Wu Chen
Board 125
• Antitumor efficacy of poxvirus-based active immunotherapy alone and in combination with subtherapeutic dosing with immune checkpoint inhibitors. (Abstract 3058)

Susan P Foy
Board 126
• Pretreatment serum levels of circulating myeloid-derived suppressor cells (MDSC) as a prognostic indicator in patients with gastrointestinal cancer. (Abstract 3059)

Masahiko Shibata
Board 127
• Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients. (Abstract 3060)

Mugdha Anand Deo
Board 128
• Phase I trial of ImmunoBody in melanoma patients. (Abstract 3061)

Poulam M. Patel
Board 129
• γδ T cells in combination with Newcastle disease virus and dendritic cell therapy as a novel immunotherapeutic approach in treating of advanced lung cancer. (Abstract 3062)

Jan Nesselhut
Board 130
• Specific increase in T-cell potency via structure-based design of a T-cell receptor for adoptive immunotherapy. (Abstract 3063)
  Karolina Malecek
  Board 131
• Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. (Abstract 3064)
  Christopher Ryan Heery
  Board 132
• A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with metastatic renal cell carcinoma. (Abstract 3065)
  Aradeep Chatterjee
  Board 133
• Fynomer-antibody fusions targeting HER2 and CD3 for selective killing of HER2 overexpressing tumor cells. (Abstract 3066)
  Richard Woods
  Board 134
• A phase I study with LTX-315, an immunogenic cell death inducer, in patients with transdermally accessible tumors. (Abstract 3067)
  Paal Brunsvig
  Board 135
• First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3. (Abstract 3068^)
  Steven J. Isakoff
  Board 136
• Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM). (Abstract 3069)
  Gordana Vlahovic
  Board 137
• Development of a personalized cellular ex vivo CBL-b silencing cancer immune therapy. (Abstract 3070)
  Marc Oliver Salzberg
  Board 138
• NY-ESO-1 specific CD4+ Thelper1 cells for immunotherapy of cancer. (Abstract 3071)
  Simone Kayser
  Board 139
• A phase Ib/IIa study of NEO-102: A therapeutic antibody for the treatment of advanced pancreatic and colorectal cancer. (Abstract 3072)
  Sandip Pravin Patel
  Board 140
• Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients. (Abstract 3073)
  Deepa Bai Jagtap
  Board 141
• An adoptive immunotherapy approach for colorectal cancer (CRC) patients. (Abstract 3074)
  Marco Bregni
  Board 142
• Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer. (Abstract 3075)
  Lawrence G. Lum
  Board 143
• A phase 1 study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximab and irinotecan in patients with advanced cancers. (Abstract 3076)
  James M. Cleary
  Board 144
• Survival effect of bi-shRNAfurin/GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to a-interferon-ELISPTOT response. (Abstract 3077)
  John J. Nemunaitis
  Board 145
• Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. (Abstract 3078)
  Joan M. Robbins
  Board 146
• Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR. (Abstract 3079)
  Marc Better
  Board 147
• PROSTVAC, PSA-targeted immunotherapy: New evidence for mechanism of action. (Abstract 3080)
  Stefanie J Mandl
  Board 148
• NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma. (Abstract 3081)
  Christopher Ryan Heery
  Board 149
• Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA-4 or anti-PD1 in murine tumor models. (Abstract 3082)
  Seema S. Kantak
Board 150
- Immunomodulatory effects of 5-azacytidine in acute myeloid leukemia. (Abstract 3083)
  
  Anne Letsch

Board 151
- 18F-fluorodeoxyglucose PET/CT imaging for predicting treatment response in patients with advanced melanoma treated with anti-PD1 immunotherapy. (Abstract 3084)
  
  Miguel Hernandez Pampaloni

Board 152
- Intratumoral vaccination with activated allogeneic dendritic cells in patients with newly diagnosed metastatic renal cell carcinoma (mRCC). (Abstract 3085)
  
  Anders Magnusson

Board 154
- Randomized phase II study of personalized peptide vaccination with cyclophosphamide pretreatment in refractory advanced biliary tract cancer patients. (Abstract 3087)
  
  Tetsuro Sasada

Board 155
- Phase I study to evaluate toxicity and feasibility of intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma. (Abstract 3088)
  
  Mark R. Albertini

Board 156
- Pilot trial of a WT-1 analog peptide vaccine in patients with high-risk myeloid neoplasms. (Abstract 3089)
  
  Jason B. Brayer

Board 157
- Long-term survival for patients with detectable metastatic melanoma at time of treatment with patient-specific tumor stem cell vaccines. (Abstract 3090)
  
  Robert Owen Dillman

Board 158
- Tolerability, humoral immune response, and disease control in phase 1 patients receiving ONT-10, a MUC1 liposomal vaccine. (Abstract 3091)
  
  John J. Nemunaitis

Board 159
- Randomized phase II study of personalized peptide vaccination in patients with advanced bladder cancer progressing after chemotherapy. (Abstract 3092)
  
  Masanori Noguchi

Board 160
- Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011. (Abstract 3093)
  
  Elizabeth Susan Gabitzsch
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS. (Abstract 3094)
Yoshihiro Yoshitake
Board 162

Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/Pca. (Abstract 3095)
Michal Podrazil
Board 163

Long-term survival of patients suffering from solid extra-cranial neoplasias after dendritic cell-based cancer immune therapy. (Abstract 3096)
Friedrich Erhart
Board 164

Phase I/IIa study of therapeutic p16INK4a vaccination in patients with HPV-associated cancers. (Abstract 3097)
Miriam Reuschenbach
Board 165

Synthetic IL-33 DNA as anti-tumor adjuvant in vivo. (Abstract 3098)
Daniel Villarreal
Board 166

Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa. (Abstract 3099)
Radek Spisek
Board 167

Antitumor effects of a nanoparticle-based vaccine targeted at human aspartyl (Asparaginyl) ß-hydroxylase (HAAH). (Abstract 3100)
Hossein A. Ghanbari
Board 168

Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial. (Abstract 3101)
Matthew P Morrow
Board 169

Impact of new oncolytic herpes simplex virus vector armed with interleukine-12 for cervical cancer therapy. (Abstract 3102)
Masahiro Kagabu
Board 170

A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors. (Abstract 3103)
Emiliano Calvo  
Board 171  
• Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients. (Abstract 3104)

Adel Jebar  
Board 172  
• Oncolytic viral therapy for malignant gliomas using myxoma virus deleted for antiapoptotic M11L gene. (Abstract 3105)

Peter A. J. Forsyth  
Board 173  
• Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I study. (Abstract 3106)

Efrat Dotan  
Board 174  
• Characterization of an anti-αrop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers. (Abstract 3107)

David M. Goldenberg  
Board 175  
• Activation of the human natural killer cells NK-92 with a lymphocyte-derived cytokine-rich supernatant. (Abstract 3108)

Ioannis F. Voutsas  
Board 176  
• The prognostic significance of ErbB-1 (EGFR), ErbB-2 (HER2), and c-MET overexpression in resectable gastric carcinoma (GC). (Abstract 3109)

Aleksandra Paliga  
Board 177  
• Combining radiotherapy and immunotherapy in the treatment of advanced cancer: A limited meta-analysis. (Abstract 3110)

Christine Zhou  
Board 178A  
• RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients. (Abstract TPS3111)

Maurenis Hernandez  
Board 178B  
• A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumor. (Abstract TPS3112)

Rocio Garcia-Carbonero  
Board 179A
• Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors. (Abstract TPS3113)
  
  *José María López-Picazo*
  
  Board 179B

• Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. (Abstract TPS3114)
  
  *Margaret K. Callahan*
  
  Board 180A

• A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. (Abstract TPS3115)
  
  *Neil Howard Segal*
  
  Board 180B

• A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies. (Abstract TPS3116)
  
  *Guillermo Garcia-Manero*
  
  Board 181A

• A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (Abstract TPS3117)
  
  *David Samuel DiCapua Siegel*
  
  Board 181B

• A phase I study of adoptive CD8+ cell therapy with or without dendritic cell vaccination in patients with metastatic melanoma. (Abstract TPS3118)
  
  *Roger Tell*
  
  Board 182A

• A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors. (Abstract TPS3119)
  
  *Rita Nanda*
  
  Board 182B

• A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. (Abstract TPS3120★)
  
  *Margaret K. Callahan*
  
  Board 183A

• First-in-human phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor NLG-919. (Abstract TPS3121)
  
  *Samir Khleif*
  
  Board 183B
• TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells. (Abstract TPS3122)
  Jobst C. von Einem
  Board 184A

• Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). (Abstract TPS3123)
  Ezra E.W. Cohen
  Board 184B

• A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer. (Abstract TPS3124)
  Hatem Hussein Soliman
  Board 185A

• A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. (Abstract TPS3125)
  Hatem Hussein Soliman
  Board 185B

• A first-in-human study of pegylated recombinant human IL-10 (AM0010), daily administered for four months in selected advanced solid tumors. (Abstract TPS3126)
  Todd Michael Bauer
  Board 186A

• A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors. (Abstract TPS3127)
  Neelesh Sharma
  Board 186B

• Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. (Abstract TPS3128)
  Dung T. Le
  Board 187A

• Randomized phase II study with dendritic cell (DC) immunotherapy in patients with resected hepatic metastasis of colorectal carcinoma. (Abstract TPS3129)
  Javier Rodriguez
  Board 187B

• Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for breast cancer patients in the adjuvant setting. (Abstract TPS3130)
  Uhi Toh
  Board 188A

• A phase 1A/1B, two-stage study of a PSA/IL-2/GM-CSF vaccine for the treatment of PSA-recurrent prostate cancer in hormone-naive and hormone-independent patients. (Abstract TPS3131)
Gregory A. Daniels
Board 188B
• A phase I study of BPX-201 vaccine plus AP1903 for chemo-naive metastatic castrate-resistant prostate cancer (mCRPC). (Abstract TPS3132)

Guru Sonpavde
Board 189A
• Local and systemic antitumor effects of activated autologous dendritic cells for intratumoral injection: A phase I/II trial. (Abstract TPS3133)

Vivek Subbiah
Board 189B
• Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC). (Abstract TPS3134)

Lukas Rob

Session Title: Patient and Survivor Care
Session Type: General Poster Session
Track: Patient and Survivor Care
Time: 8:00 AM - 11:45 AM
Location: S Hall A2

Board 190
• Fentanyl exposure after subcutaneous and transdermal administration: Results from a population pharmacokinetic study in cancer patients. (Abstract 9540)
  Astrid W. Oosten
Board 191
• Intensity of end-of-life care among adolescents and young adults with cancer. (Abstract 9541)
  Jennifer W. Mack
Board 192
• Multimorbidity and racial disparities in use of hospice by older patients dying from cancer. (Abstract 9542)
  Siran M. Koroukian
Board 193
• Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution. (Abstract 9543)
  Younak Choi
- Patterns of chemotherapy near the end of life for patients receiving palliative bone radiotherapy. (Abstract 9544)
  
  *Powell Perng*

- Evaluation of falls in older adults in a comprehensive cancer center: How are we doing? (Abstract 9545)
  
  *Emily Jean Guerard*

- A prospective study to evaluate the Vulnerable Elders Survey-13 (VES-13) as a tool to identify frail older cancer patients (pts). (Abstract 9546)
  
  *Laura Biganzoli*

- Changes in items of a comprehensive geriatric assessment (CGA) during follow-up: Results from the IN-GHO registry. (Abstract 9547)
  
  *Friedemann Honecker*

- The underutilization of occupational and physical therapy for older adults with cancer. (Abstract 9548)
  
  *Mackenzi Pergolotti*

- Geriatric oncology: Comprehensive geriatric assessment tools (CGA) implementation and interdisciplinary clinical approach for elderly patients (pts) in AC Camargo Cancer Center (ACCCC), Sao Paulo, Brazil. (Abstract 9549)
  
  *Aldo A. Dettino*

- Age as an independent predictor of chemotherapy treatment decisions in 20 common cancers. (Abstract 9550)
  
  *Peter Hall*

- Multidisciplinary risk assessment to reveal cancer treatments in unfit cancer patients. (Abstract 9551)
  
  *Pascaline Boudou-Rouquette*

- Association of frailty markers with treatment decision in patients seen in oncogeriatric clinic: Results from the ASRO pilot study. (Abstract 9552)
  
  *Anais Farcet*

- Frailty markers for prediction of mortality in first-line chemotherapy for colon cancer patients: Results of MOST/ASRO 101 study. (Abstract 9553)
Frederique Retornaz
Board 204
• Outcomes of invasive mechanical ventilation in elderly patients with metastatic cancer. (Abstract 9554)
Achuta Kumar Guddati
Board 205
• Phase angle for prognostication of survival in patients with advanced cancer. (Abstract 9555)
David Hui
Board 206
• Availability of single-fraction palliative radiotherapy for cancer patients receiving end-of-life care within the Veterans Healthcare Administration. (Abstract 9556)
Drew Moghanaki
Board 207
• Phase II clinical trial of uncaria tomentosa (cat’s claw) in patients with advanced solid tumors. (Abstract 9557)
Larissa Carvalho Lopes De Paula
Board 208
• Assessing 2-month clinical prognosis in patients with solid tumors: Final results of PRONOPALL study. (Abstract 9558)
Hugues Pierre Bourgeois
Board 209
• Spirituality and quality of life among caregivers of advanced cancer patients. (Abstract 9559)
Tai Chung Lam
Board 210
• Differences between patient and caregiver ratings of advanced cancer patients' quality of life and correlates of their disagreement. (Abstract 9560)
Tai Chung Lam
Board 211
• Change in palliative performance scale score as prediction of survival in patients with advanced cancer. (Abstract 9561)
Yong Joo Lee
Board 212
• Intensive care unit admissions and in-hospital mortality in patients admitted through the emergency department of a comprehensive cancer center. (Abstract 9562)
Ahmed F. Elsayem
Board 213
• Pre- and postradiation lymphopenia predicts survival in management of bone metastases. (Abstract 9563)
Sara R. Alcorn
• Previous cancer of spouse as a predictor for mortality after personal diagnosis of cancer. (Abstract 9564)
  Tamar Peretz

• Biopsychosocial predictors of pain among women recovering from surgery for gynecologic cancer. (Abstract 9565)
  Kelsey R. Honerlaw

• Effect of contralateral prophylactic mastectomy on quality of life in women undergoing surgery for breast cancer: A prospective study. (Abstract 9566)
  Chang Xia

• Default of cancer treatment association with psychological distress and desire for psychological support. (Abstract 9567)
  Caryn Mei-Hsien Chan

• Mental mood of gynecologic cancer patients assessed by distress and impact thermometer (DIT; a two-item, self-report questionnaire) and hospital anxiety and depression scale (HADS; a 14-item, self-report questionnaire) during the initial treatment in the first 6 months: KCOG-G1103 study. (Abstract 9568)
  Yoshio Itani

• The subjective quality of life of young patients with breast cancer and their partners. (Abstract 9569)
  Laurence Vanlemmens

• Has health-related quality-of-life assessment in EORTC clinical trials helped to obtain regulatory approvals and change clinical practice? A review of the EORTC experience in cancer clinical trials. (Abstract 9570)
  Efstathios Zikos

• Mobile cognitive assessment battery (MCAB) for assessment of cancer-related cognitive changes. (Abstract 9571)
  Shelli Kesler

• Feasibility of neurocognitive and psychological assessments in allogeneic stem cell transplantation: A pilot study. (Abstract 9572)
  Tara K. Gregory
• Evaluation of an online, skill-building, group intervention for cancer patients and caregivers: Pillars4Life. (Abstract 9573)
  Jonathan David O’Donnell
  Board 224

• Quality of life of young mothers with breast cancer in Germany. (Abstract 9574)
  Dorothea Fischer
  Board 225

• Social and perceptual influences on alcohol consumption in cancer survivors. (Abstract 9575)
  Lawson Eng
  Board 226

• Factors influencing advanced cancer patients’ preferences for quality or length of life. (Abstract 9576)
  Eva C. Winkler
  Board 227

• Traumatic stress symptoms in patients with acute leukemia (AL). (Abstract 9577)
  Gary Rodin
  Board 228

• Marital distress (MD), quality of life, and psychological morbidity among advanced cancer patients (ACP) in phase I trials and their spousal caregivers (SC). (Abstract 9578)
  Fay J. Hlubocky
  Board 229

• Persistent pain following breast cancer surgery: A case-control study. (Abstract 9579)
  Sara N. Edmond
  Board 230

• Survival differences by race/ethnicity in adolescents and young adults diagnosed with non-Hodgkin lymphoma. (Abstract 9580)
  Chun Chao
  Board 231

• The potential role of pNF-H, a biomarker of white matter damage in central nervous system, as a predictive marker of chemotherapy-induced cognitive impairments. (Abstract 9581)
  Akina Natori
  Board 232

• Follow up of 1,001 adults and children after fertility preservation for oncologic conditions within a publicly financed health care program. (Abstract 9582)
  Kenny A Rodriguez-Wallberg
  Board 233

• Effect of exercise on cancer-associated cognitive dysfunction: A proof-of-concept randomized controlled trial. (Abstract 9583)
Kristin Campbell
Board 234
• Patients’ expectations of oncologists and primary care providers (PCPs) in addressing reproductive and sexual health. (Abstract 9584)

Ying Wang
Board 235
• Feasibility of using home-based mobile sensors for remote patient monitoring in cancer care and prevention. (Abstract 9585)

Susan K. Peterson
Board 236
• Sexual problems of female cancer survivors compared to women without cancer. (Abstract 9586)

Ah Reum An
Board 237
• Acute changes in endothelial function with cisplatin among germ cell tumor (GCT) patients (Pts). (Abstract 9587)

Darren Richard Feldman
Board 238
• Characterizing self-reported memory problems in adult-onset cancer survivors in the United States: Importance of sleep duration and insomnia. (Abstract 9588)

Pascal Jean-Pierre
Board 239
• Genetic testing referral patterns and clinical outcomes among high-risk breast cancer survivors. (Abstract 9589)

Rashmi Krishna Murthy
Board 240
• Long-term survivors in phase I clinical trials: Who are they and what predicts their survival? (Abstract 9590)

Begona Jimenez Rodriguez
Board 241
• Ventricular arterial coupling in early breast cancer patients following treatment with anthracycline-containing adjuvant chemotherapy. (Abstract 9591)

Graeme John Koelwyn
Board 242
• Chemotherapy-induced amenorrhea (CIA) risk associated with taxane/platinum-based chemotherapy in young (=45 years) breast cancer patients. (Abstract 9592)

Priyanka Sharma
Board 243
• Cardiovascular mortality (CVM) among testicular nonseminoma (TN) survivors after chemotherapy (CHEM) or surgery (SURG). (Abstract 9593)
  Chunkit Fung
  Board 244

• Long-term quality of life among localized prostate cancer survivors: Qalipro population-based study. (Abstract 9594)
  Anne-Valérie Guizard
  Board 245

• Chemotherapy-induced ovarian failure in young breast cancer patients: The role of vascular toxicity. (Abstract 9595)
  Irit Ben-Aharon
  Board 246

• Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors. (Abstract 9596)
  Patricia M. Sheean
  Board 247

• Impact of current treatment status on QOL in cancer survivors. (Abstract 9597)
  Eon Sook Lee
  Board 248

• Association of physical activity with cardiorespiratory fitness and cardiac function in cancer survivors with chemotherapy-related heart failure. (Abstract 9598)
  Karen Basen-Engquist
  Board 249

• Leukocyte telomere length and risk of secondary primary tumors in long-term breast cancer survivors. (Abstract 9599)
  Maria Alma Rodriguez
  Board 250

• Factors associated with bone fractures following hematopoietic stem cell transplantation. (Abstract 9600)
  Xerxes Pundole
  Board 251

• Risk factors and prevalence of cognitive deficits in women with gynecologic malignancies. (Abstract 9601)
  Anne Van Arsdale
  Board 252

• Breast imaging two years post-breast conserving therapy (BCT): Do more frequent mammograms (MMG) yield benefits? (Abstract 9602)
  Jingjing Hu
  Board 253
• Trends in health-related quality of life (HRQoL) and income over time in older adults with and without cancer: Evidence from the Surveillance, Epidemiology, and End Results–Medicare Health Outcomes Survey (SEER–MHOS) linked database. (Abstract 9603)
  Veena Shankaran
  Board 254

• Arterial elasticity in testicular cancer survivors. (Abstract 9604)
  Anne Hudson Blaes
  Board 255

• Patient-reported outcomes from adolescent/young adult (AYA) cancer survivors. (Abstract 9605)
  James M. Metz
  Board 256

• Dose delays, dose reductions, and relative dose intensity in patients with cancer who received (neo)adjuvant chemotherapy in community oncology practices. (Abstract 9606)
  Menaka Bhor
  Board 257

• A multicenter observational study comparing physician-assessed febrile neutropenia (FN) risk and prediction-model severe neutropenia (SN) or FN risk in patients (pts) with nonmyeloid malignancies. (Abstract 9607)
  Gary H. Lyman
  Board 258

• Palonosetron (PAL) in combination with 1-day versus 3-days dexamethasone (DEX) to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin (TC). (Abstract 9608)
  Naoto Furukawa
  Board 259

• Perceptions regarding the value of the physical examination in patients with advanced cancer: A survey study. (Abstract 9609)
  Kunal C. Kadakia
  Board 260

• A randomized phase II study evaluating the use of prydoxine to prevent hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. (Abstract 9610)
  Akiyo Yoshimura
  Board 261

• Prevention of irinotecan-induced diarrhea by probiotics: Randomized double-blind, placebo-controlled phase III study. (Abstract 9611)
  Michal Mego
  Board 262
• A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). (Abstract 9612)
Daniel Louis Hertz
Board 263

• Use of aprepitant in uncontrolled delayed nausea and vomiting associated with preparative regimens in stem cell transplantation: A retrospective analysis. (Abstract 9613)
Linh Tran
Board 264

• Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy. (Abstract 9614^)
Caicun Zhou
Board 265

• A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial. (Abstract 9615)
Cesar Augusto Santa-Maria
Board 266

• Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized crossover study. (Abstract 9616)
Saroj Vadhan-Raj
Board 267

• Noninvasive liver fibrosis index changes during chemotherapy: Marker for oxaliplatin-induced hepatic sinusoidal obstruction syndrome. (Abstract 9617)
Sehhoon Park
Board 268

• Enobosarm and lean body mass in patients with non-small cell lung cancer. (Abstract 9618)
Jeffrey Crawford
Board 269

• Effect of body mass index and menopausal disorders during menopause on vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: A prospective multicenter cohort study of patient-reported outcomes. (Abstract 9619)
Kaori Tane
Board 270

• Prediction of major complications in patients with solid tumors and apparently stable febrile neutropenia: Validation of the CISNE risk score. (Abstract 9620)
Javier Espinosa
Board 271
• The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (The QoLiTax-Trial of the Arbeitsgemeinschaft Internistische Onkologie, AIO). (Abstract 9621)
  Claudia Pauligk
  Board 272
• Scrambler therapy for treatment of chemotherapy-induced peripheral neuropathy. (Abstract 9622)
  Breanna L Weisbrod
  Board 273
• Bone health in prostate patients: An opportunity for screening and intervention. (Abstract 9623)
  George A. Dawson
  Board 274
• Clinical risk prediction in anthracycline cardiotoxicity. (Abstract 9624)
  Bonnie Ky
  Board 275
• Outcomes of early palliative care referrals for patients with advanced lung cancer. (Abstract 9625)
  Sriram Yennu
  Board 276
• Mortality from malignant bowel obstruction in hospitalized U.S. cancer patients. (Abstract 9626)
  Olatunji Boladale Alese
  Board 277
• Predicting the risk of gastrointestinal (GI) toxicity in early colon cancer (CC) patients treated with adjuvant chemotherapy: Developing a GI toxicity scoring system. (Abstract 9627)
  Gillian Gresham
  Board 278
• Randomized phase II pilot study of loratadine for the prevention of bone pain caused by pegfilgrastim. (Abstract 9628)
  Julia Moukharskaya
  Board 279
• The effects of oncologists’ physical activity recommendations and information packages on level of physical activity and the quality of life in cancer survivors. (Abstract 9629)
  Ji-Hye Park
  Board 280
• Effects of a 12-week home-based exercise program on quality of life, psychological health, and the level of physical activity in colorectal cancer survivors. (Abstract 9630)
  Ji Young Kim
• PROCAPP: A randomized, open-label phase III trial comparing mapisal and urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot skin reaction (HFSR) in patients (pts) with gastrointestinal (GI) tumors or breast cancer—A study of the AIO Quality of Life Working Group. (Abstract 9631)
  Deniz Gencer

• Pegfilgrastim (P) administration after 24, 72, or 96 hours (h) to allow dose-dense (DD) anthracycline- and taxane-based chemotherapy (CT) in breast cancer (BC) patients (pts): A single-center experience within the GIM2 randomized phase III study. (Abstract 9632)
  Matteo Lambertini

• Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC). (Abstract 9633)
  Ian D. Schnadig

• Risk of severe diarrhea associated with ipilimumab in cancer patients. (Abstract 9634)
  Robert Charles Hendler

• Frequency, intensity, and correlates of financial distress (FD) among advanced cancer patients (AdCa). (Abstract 9635)
  Marvin Omar Delgado-Guay

• Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC). (Abstract 9636)
  Laszlo Urban

• Symptoms in gastrointestinal stromal tumors. (Abstract 9637)
  Loretta A. Williams

• Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC). (Abstract 9638)
  Bernardo Leon Rapoport

• Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is). (Abstract 9639)
  Ole-Petter Riksfjord Hamnvik
• Survival benefit with low-molecular-weight heparin in patients with advanced solid tumors: A post hoc analysis of PROTECHT trial. (Abstract 9640)
  Sandro Barni

• A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study. (Abstract 9641^)
  Michele Spina

• Quality of life (QOL), mood, and prognostic awareness during hospitalization for hematopoietic stem cell transplantation (HSCT). (Abstract 9642)
  Areej El-Jawahri

• Treating diabetic patients with chemotherapy: Single-center experience of toxicity and outcomes. (Abstract 9643)
  Jenny F. Seligmann

• Prediction and early detection of anthracycline-related cardiotoxicity using cardiac biomarkers. (Abstract 9644)
  Patrick Lawson Stevens

• Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy. (Abstract 9645)
  Ralph V. Boccia

• Management approaches and outcomes of lung cancer patients hospitalized for malignant pleural effusions. (Abstract 9646)
  Madhusmita Behera

• A phase II randomized, double-blind placebo-controlled trial of an antiemetic, 6-gingerol in solid tumor patients receiving moderately to highly emetogenic adjuvant chemotherapy. (Abstract 9647)
  Jitprapa Konmun

• A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) versus palonosetron (PALO) for preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately (MEC) or highly (HEC) emetogenic chemotherapy: Does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions? (Abstract 9648)
  Harry Raftopoulos
• Sleep problems and increased risk of mortality in the context of advanced cancer. (Abstract 9649)
  Kevin P Collins

• Cancer patients and their information needs for prediction of symptom burden during and after treatment: Implications for symptom management. (Abstract 9650)
  Luke Joseph Peppone

• Understanding of early-phase clinical trials among a cohort of advanced cancer patients with limited standard treatment options. (Abstract 9651)
  Daniel Paul Dohan

• Nervous system sequelae of chemotherapy treatment: Associations and proposed mechanisms. (Abstract 9652)
  Kelly N. H. Nudelman

• Prechemotherapy cognitive function in 362 breast cancer (BC) patients and 362 age-paired controls without cancer: A nationwide longitudinal trial conducted through the University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) Research Base (RB). (Abstract 9653)
  Michelle Christine Janelsins

• Use, misuse, and overuse of white cell growth factors (GF) in community oncology practices in southeastern United States. (Abstract 9654)
  William J. Hrushesky

• Single-center, prospective pilot study to evaluate advance care planning implementing the 3 Questions and 3 Elements to identify an informed health care proxy in an outpatient oncology palliative care clinic. (Abstract TPS9655)
  Eric Roeland

• Quality of life (QOL) measurement in patients receiving neoadjuvant therapy in the I-SPY 2 trial. (Abstract TPS9656)
  Michael Hwang

• POWER-remote: A randomized study evaluating the effect of a remote-based weight loss program on biomarkers in women with early-stage breast cancer. (Abstract TPS9657)
  Cesar Augusto Santa-Maria
• Prevalence of hypogonadism in previously treated germ cell tumor patients. (Abstract TPS9658)
  Trent James Miller
  Board 307A

• Phase II trial of inflammation markers and symptom control in metastatic lung cancer: Insync. (Abstract TPS9659)
  Chipman Robert Geoffrey Stroud
  Board 307B

• Scalp cooling alopecia prevention trial (SCALP). (Abstract TPS9660)
  Julie R. Nangia
  Board 308A

• SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. (Abstract TPS9661)
  Annie Young
  Board 308B

• A randomized placebo-controlled phase III study of duloxetine for treatment of aromatase inhibitor (AI)-associated musculoskeletal symptoms in women with early-stage breast cancer: SWOG S1202. (Abstract TPS9662)
  N. Lynn Henry
  Board 309A

• Incidence of hypersensitivity reactions (HSR) in patients receiving reduced doses of dexamethasone as prophylaxis for carboplatin and paclitaxel in gynecologic malignancies. (Abstract TPS9663)
  Justin Liauw
  Board 309B

• Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC). (Abstract TPS9664)
  Stephen Joseph Noga

Session Title: 50 Years of Precision Medicine: Advances in the Field and Prospective and Innovative Randomized Clinical Trials

Session Type: Education Session

Track: Clinical Trials

Time: 9:45 AM - 11:00 AM

Location: S100bc

• Advances in Precision Medicine: Prospective Clinical Trials
  Apostolia Maria Tsimberidou, MD, PhD
• Combining Immune and Targeted Therapies in Melanoma: A Paradigm for Other Tumor Types
  *Alexander M. Eggermont, MD, PhD*

• The Vision of Precision Medicine in the Next 50 Years
  *Richard L. Schilsky, MD - Chair*

• Panel Question and Answer

**Session Title:** How to Talk with Your Pathologist about Molecular Testing  
**Session Type:** Education Session  
**Track:** Lung Cancer  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E Arie Crown Theater

• What Are We Talking About: Next-Generation Sequencing, Sanger Sequencing, etc.
  *Pasi A. Janne, MD, PhD - Chair*

• Tissue is the Issue: The Pathologist’s Role in Facilitating Molecular Analysis
  *Dara Aisner, MD, PhD*

• The Practitioner’s Guide to Using Molecular Testing
  *Jan A. Nowak, MD, PhD*

• Panel Question and Answer

**Session Title:** Quality and Value in Gynecologic Cancer Care: Do We Get What We Pay For?  
**Session Type:** Education Session  
**Track:** Gynecologic Cancer  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E354a

• Quality and Value in Gynecologic Cancer Care: Measuring and Proving Benefits Under the Affordable Care Act
  *Matthew A. Powell, MD - Chair*

• How Do I Know My Gynecologic Cancer Surgeon Is Providing Quality Care?
  *William Cliby, MD*

• Can We Maximize Both Value and Quality in Gynecologic Cancer Care? A Work in Progress
  *Laura Jean Havrilesky, MD, MHSc*

• Panel Question and Answer

**Session Title:** Radiopharmaceuticals: Spanning Hematologic Malignancies to Solid Tumors  
**Session Type:** Education Session  
**Track:** Developmental Therapeutics
**Time:** 9:45 AM - 11:00 AM  
**Location:** S100a

- **Targeted Alpha-Particle Nano-Generator Actinium-225-Lintuzumab in Hematologic Malignancies**  
  *Joseph G. Jurcic, MD*

- **Preclinical Models of Radioimmunotherapy/Antibody Conjugates: Translation to the Clinic**  
  *George Sgouros, PhD - Chair*

- **Alpha Emitter Radium-223 in the Management of Solid Tumors: Current Status and Future Directions**  
  *Sten Nilsson, MD, PhD*

- **Panel Question and Answer**

**Session Title:** The Evolution of Our Molecular Understanding of Colorectal Cancer: What We Are Doing Now, What the Future Holds, and How Tumor Profiling Is Just the Beginning  
**Session Type:** Education Session  
**Track:** Gastrointestinal (Colorectal) Cancer  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E Hall D1

- **What Is the Current Status of Biomarkers in Use for the Treatment of Patients with Colorectal Cancer?**  
  *Sabine Tejpar, MD, PhD*

- **Molecular biomarker characterization and subtyping of colorectal cancer: next-generation of matched targeted therapies**  
  *Josep Tabernero, MD, PhD - Chair*

- **What Is Tumor Heterogeneity and How Will This Play a Role in the Development of Agents to Treat Colorectal Cancer?**  
  *Charles Swanton, MD, PhD*

- **Panel Question and Answer**

**Session Title:** The Present and Future of the State of the Art in Health Services Research  
**Session Type:** Education Session  
**Track:** Health Services Research  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E253

- **Health Services Research: Where Are We and Where Are We Going?**  
  *Craig Earle, MD, MSc - Chair*

- **What's New and Exciting in Health Services Research Methodology?**  
  *Robin Yabroff, PhD*
• Panel Question and Answer

**Session Title:** Identification and Management of Systemic and Cutaneous Toxicities from Vemurafenib, Dabrafenib, Trametinib, and Ipilimumab for Melanoma - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Track:** Melanoma/Skin Cancers  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E451a

- Identification and Management of Toxicities from Immune-Checkpoint Blockades  
  *Jeffrey S. Weber, MD, PhD*  
- Recognition and Management of Cutaneous Toxicities from Kinase Inhibitors and Immunotherapies  
  *Mario E. Lacouture, MD*

**Session Title:** Toxicity Management in Head and Neck Cancer - Ticketed Session  
**Session Type:** Clinical Problems in Oncology Session  
**Track:** Head and Neck Cancer  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E451b

- Tyrosine Kinase Inhibitor Toxicities  
  *Jill Gilbert, MD - Chair*  
- Mucositis: Etiology, Clinical Impact, and Treatment  
  *Stephen T. Sonis, DMD, DMSc*  
- Dysphagia Etiologies, Assessment, and Interventions  
  *Kate A. Hutcheson, PhD*

**Session Title:** Pediatric Oncology II  
**Session Type:** Oral Abstract Session  
**Track:** Pediatric Oncology  
**Time:** 9:45 AM - 12:45 PM  
**Location:** S504

- Chair  
  *Clare Twist, MD*  
- Chair  
  *Sarah K. Tasian, MD*  
- Breast cancer in childhood cancer survivors not treated with chest-directed radiation in the Childhood Cancer Survivor Study (CCSS). (Abstract 10009)  
  *Tara O. Henderson*
- Alkylationing agent exposure and sperm concentration in adult survivors of childhood cancer: A report from the St. Jude Lifetime (SJLIFE) Cohort Study. (Abstract 10010)
  
  Daniel M. Green

- Multicenter study assessing tumor molecular profiles in advanced pediatric solid tumors. (Abstract 10011)
  
  Katherine A. Janeway

- What’s in an exome? Diversity of diagnostic and incidental findings revealed by clinical tumor and germline sequencing of 100 children with solid tumors. (Abstract 10012)
  
  D. Williams Parsons

- Molecular Profiling of Tumors: Are We Ready for Prime Time?
  
  Stephen Hunger, MD

- Panel Question and Answer
  
  Panel Discussion

- Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children’s Oncology Group (COG) study AALL03N1. (Abstract 10013)
  
  Wendy Landier

- The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) protocol AALL0433. (Abstract 10014)
  
  Glen Lew

- Outcome of childhood T-cell acute lymphoblastic leukemia (T-ALL): Results from DFCI protocol 05-001. (Abstract 10015)
  
  Andrew E. Place

- Outcomes in T-Cell Acute Lymphoblastic Leukemia: No Longer the Bad Actor
  
  Sima Jeha, MD

- Panel Question and Answer

- The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG) Studies AALL0331 and AALL0232. (Abstract 10016)
  
  Naomi Joan Winick

- The effects of sodium thiosulfate (STS) on cisplatin-induced hearing loss: A report from the Children's Oncology Group. (Abstract 10017)
  
  David Robert Freyer

- Alleviating Toxicity: Risks versus Benefits
  
  Maryam Fouladi, MD

- Panel Question and Answer
  
  Panel Discussion
Session Title: Accelerated Aging among Cancer Survivors: From Pediatrics to Geriatrics
Session Type: Education Session
Track: Patient and Survivor Care
Time: 11:30 AM - 12:45 PM
Location: S404
- The Effects of Cancer Treatment on Aging Cells and Comorbidities
  Harvey Jay Cohen, MD
- Accelerated Aging in Cancer Survivors: Lessons Learned from Longitudinal Follow-up Studies
  Kirsten K. Ness, PT, PhD
- Health Interventions to Improve Morbidity and Mortality in Survivors of Cancer
  Tara O. Henderson, MD, MPH - Chair
- Panel Question and Answer

Session Title: Developing a Usable Biomarker: Odyssey of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma—From a Journal Report to a Multinational Clinical Trial
Session Type: Education Session
Track: Clinical Trials
Time: 11:30 AM - 12:45 PM
Location: S100a
- Critical Steps: From an International Collaboration to Harmonization in Biomarker Use
  Quynh-Thu Le, MD
- How to Develop a Usable Biomarker for a Clinical Trial
  Lisa M. McShane, PhD
- Regulatory and Funding Issues in Using Integral Biomarkers in an International Clinical Trial
  Bhupinder Singh Mann, MBBS - Chair
- Panel Question and Answer

Session Title: Ovarian and Cervix Avatars: The Key to Individualized Therapy?
Session Type: Education Session
Track: Gynecologic Cancer
Time: 11:30 AM - 12:45 PM
Location: E354a
- Ovatars: Using Patient-Derived Xenografts for Selecting Best Therapies
  Paul Haluska, MD, PhD - Chair
- Optimizing Cervix Cancer Therapies Using Avatar Models
  Helen Mackay, MD
• Overcoming Platinum Resistance in Ovarian Cancer
  *Clare L. Scott, MBBS PhD*
  
  • Panel Question and Answer

**Session Title:** Tools for the Best Outcomes in the Management of Brain Metastases  
**Session Type:** Education Session  
**Track:** Central Nervous System Tumors  
**Time:** 11:30 AM - 12:45 PM  
**Location:** E450

- The Practicalities of Radiotherapy for Managing Central Nervous System Metastases: Benefits and Limitations  
  *Laurie E. Gaspar, MD, MBA - Chair*
- Chasing the Offenders: Systemic Therapies Applied to Metastases in Brain and Spinal Fluid  
  *Roisin M. Connolly, MD*
- Symptom Management for Patients with Brain Metastases and Leptomeningeal Disease  
  *Jeffrey J. Raizer, MD*
  
  • Panel Question and Answer

**Session Title:** What We Can Learn from International Health Care Systems: Approaching Sustainable Cancer Care from a Global Perspective  
**Session Type:** Education Session  
**Track:** Health Services Research  
**Time:** 11:30 AM - 12:45 PM  
**Location:** E253

- Overview of Global Health Care Systems: How Nations Respond to Scarce Resouces and High Demand in Cancer Care  
  *Lawrence Brown, PhD - Chair*
- Global Response to Cancer Care: The World Health Organization Approach  
  *Andreas Ullrich, MD, MPH*
- European Approaches to Cost Containment in Cancer Care  
  *Richard Sullivan, PhD*
  
  • Panel Question and Answer

**Session Title:** Ask the Specialist: Cardiac Complications of Cancer Treatments - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Track:** Patient and Survivor Care  
**Time:** 11:30 AM - 12:45 PM  
**Location:** E451a
• A Cardiologist's Viewpoint: Management of Cancer Treatment-Related Cardiac Problems  
  Daniel John Lenihan, MD

**Session Title:** Rare Genitourinary Tumors: Lethal Prostate Cancer Variants, Non-Clear Cell Renal Cell Carcinoma, and Penile Cancer - Ticketed Session  
**Session Type:** Clinical Problems in Oncology Session  
**Track:** Genitourinary Cancer  
**Time:** 11:30 AM - 12:45 PM  
**Location:** E451b  
• Lethal Prostate Cancer Variants: Neuroendocrine Prostate Cancer and Other Subtypes  
  Christopher Logothetis, MD - Chair  
• Penile Cancer Management: The Role of Chemotherapy  
  Lance C. Pagliaro, MD  
• Genetics and Biochemical Alterations Associated with Non-Clear Cell Renal Cell Carcinoma Subtypes  
  Ramaprasad Srinivasan, MD, PhD

**Session Title:** Immunobiology and Immunotherapy  
**Session Type:** Clinical Science Symposium  
**Track:** Head and Neck Cancer  
**Time:** 11:30 AM - 1:00 PM  
**Location:** S100bc  
• Chair  
  Robert L. Ferris, MD, PhD  
• Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer. (Abstract 6009)  
  Vassiliki Saloura  
• Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-positive versus HPV-negative head and neck squamous cell carcinoma. (Abstract 6010)  
  Simona Partlova  
• Immunity as a Prognostic Biomarker  
  John H Lee, MD  
• A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. (Abstract 6011)  
  Tanguy Y. Seiwert  
• The Immune System as a Therapeutic Target  
  Robert L. Ferris, MD, PhD  
• Panel Question and Answer
**Session Title:** Plenary Session Including the Science of Oncology Award and Lecture  
**Session Type:** Plenary Session  
**Track:** Special Session  
**Time:** 1:00 PM - 4:00 PM  
**Location:** N Hall B1

- Co-Chair  
  *Clifford A. Hudis, MD, FACP*

- Co-Chair  
  *Jedd D. Wolchok, MD, PhD*

- Do Some Human Cancers Originate from Infections Transmitted from Domestic Animals?  
  *Harald zur Hausen, MD*

- Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. (Abstract LBA1)  
  *Olivia Pagani*

- Discussion  
  *Nancy E. Davidson, MD*

- Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. (Abstract LBA2)  
  *Christopher Sweeney*

- Discussion  
  *Michael J. Morris, MD*

- CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). (Abstract LBA3)  
  *Alan P. Venook*

- Discussion  
  *Josep Tabernero, MD, PhD*

- First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). (Abstract LBA4)  
  *Martine J. Piccart-Gebhart*

- Discussion  
  *George W. Sledge, MD*
**Session Title:** Plenary Session Simulcast  
**Session Type:** Plenary Session  
**Track:** Special Session  
**Time:** 1:00 PM - 4:00 PM  
Location: E Hall D1

**Session Title:** Post-Plenary Discussion I: Genitourinary Cancer  
**Session Type:** Special Session  
**Track:** Special Session  
**Time:** 4:30 PM - 5:00 PM  
Location: S100bc
- Chair  
  Ian Tannock, MD, PhD - Chair
- Speaker  
  Christopher Sweeney, MBBS
- Speaker  
  Michael J. Morris, MD
- Speaker  
  Maha Hussain, MD, FACP

**Session Title:** Eight Days a Week: Managing Cumulative Expectations for the Busy Oncology Provider  
**Session Type:** Education Session  
**Track:** Ethics  
**Time:** 4:45 PM - 6:00 PM  
Location: E253
- Cumulative Expectations: Making It Work in Community Oncology  
  Stephen S. Grubbs, MD
- Historical Reflections of the Obligaions of an Academic and Clinical Oncologist  
  David H. Johnson, MD
- Managing Cumulative Expectations in Oncology: Challenges and Potential Solutions  
  Amy Pickar Abernethy, MD, PhD - Chair
- Panel Question and Answer
**Session Title:** Follow-up Imaging in Lymphoma: A Debate on Its Use  
**Session Type:** Education Session  
**Track:** Lymphoma and Plasma Cell Disorders  
**Time:** 4:45 PM - 6:00 PM  
**Location:** E Arie Crown Theater

- **Introduction**  
  *Kenneth Robert Carson, MD - Chair*
- **Con:** We Are Not Ready to Abandon Post-treatment Imaging for Patients with Lymphoma  
  *Andrew David Zelenetz, MD, PhD*
- **Pro:** We Should Abandon Post-treatment Imaging for Patients with Lymphoma  
  *James O. Armitage, MD*
- **Panel Question and Answer**

**Session Title:** Hype versus Hope: Repurposing Metformin, Vitamin D, Aspirin, Beta-Blockers, and Folic Acid for Cancer  
**Session Type:** Education Session  
**Track:** Cancer Prevention/Epidemiology  
**Time:** 4:45 PM - 6:00 PM  
**Location:** S404

- **Design and Methodologic Issues**  
  *Dawn L. Hershman, MD, MS*
- **Metformin and Vitamin D**  
  *Pamela Jean Goodwin, MD, MSc, FRCP - Chair*
- **Updates on Acetylsalicylic Acid/Anti-inflammatories, B-Blockers, and Folic Acid**  
  *John A. Baron, MD*
- **Panel Question and Answer**

**Session Title:** Immunotherapy: Transforming Frustration to Cure in the Next 50 Years  
**Session Type:** Education Session  
**Track:** Central Nervous System Tumors  
**Time:** 4:45 PM - 6:00 PM  
**Location:** E450

- **Systemic and Central Nervous System Immunology: The Rules of Engagement**  
  *David Hafler, MD, MSc - Chair*
- **Where We Stand with Immunotherapy for Glioma: Illusion or Realistic Prospects?**  
  *Pierre-Yves Dietrich, MD*
• The Value of EGFRvIII as the Target for Glioma Vaccines
  Pedro R. Lowenstein, MD, PhD
• Panel Question and Answer

**Session Title:** Moving Forward in Advanced Prostate Cancer Clinical Development  
**Session Type:** Education Session  
**Track:** Genitourinary Cancer  
**Time:** 4:45 PM - 6:00 PM  
**Location:** E Hall D2

- Molecular Characterization and Clinical Utility of Circulating Tumor Cells  
  *Johann Sebastian De Bono, PhD, MSc - Chair*
- Moving beyond PCWG2: Identifying Criteria for the Next Generation of Clinical Trials  
  *Howard I. Scher, MD*
- Subclassification of Prostate Cancer for the Delivery of Precision Medicine  
  *Levi A. Garraway, MD, PhD*
• Panel Question and Answer

**Session Title:** Novel Molecular and Metabolic Targets in Sarcoma  
**Session Type:** Education Session  
**Track:** Sarcoma  
**Time:** 4:45 PM - 6:00 PM  
**Location:** S406

- Identification of Novel Targets in Sarcoma  
  *Gary K. Schwartz, MD*
- Harnessing the Unique Biology of Pediatric and Wild-Type Gastrointestinal Stromal Tumor  
  *Lee J. Helman, MD*
- Novel Approaches to Targeting Metabolic Pathways in Sarcoma  
  *Brian Andrew Van Tine, MD, PhD - Chair*
• Panel Question and Answer

**Session Title:** Streamlining Breast Cancer Care: Opportunities and Challenges  
**Session Type:** Education Session  
**Track:** Breast Cancer  
**Time:** 4:45 PM - 6:00 PM  
**Location:** N Hall B1

- Local Therapy for Patients with Early-Stage Breast Cancer and Ductal Carcinoma In Situ: Balancing Value and Outcome
Monica Morrow, MD - Chair

- Imaging Patients with Breast Cancer: How to Be Value Conscious from Diagnosis, Survivorship, to Metastatic Disease
  Janie M. Lee, MD, MSc
- Value-Based Approach to Systemic Therapy in Patients with Breast Cancer: What Is the Evidence?
  Michael J. Hassett, MD, MPH
- Panel Question and Answer

Session Title: The 2013 Institute of Medicine Report on Delivering Quality Cancer Care: What Needs to Happen
Session Type: Education Session
Track: Health Services Research
Time: 4:45 PM - 6:00 PM
Location: E354a

- Patient-Centered Communication and Shared Decision Making
  Patricia A. Ganz, MD - Chair
- High-Quality Cancer Care: Where We Are and How We Can Improve Performance
  George W. Sledge, MD
- Accessible and Affordable Cancer Care
  Michael N. Neuss, MD
- Panel Question and Answer

Session Title: The Future Is Now: Incorporating Electronic Health Records, Web-Based Decision Tools, and Social Media into Your Clinical Practice
Session Type: Education Session
Track: Professional Development
Time: 4:45 PM - 6:00 PM
Location: S504

- Guidelines for the Appropriate Use of Social Media and Social Networking in Medical Practice
  Michael Fisch, MD, MPH
- Emerging Tools for Collecting Patient-Reported Outcomes in Research and Clinical Practice
  Laura E. Strong, PhD
- Modern Methods of Communicating Medical Information to Health Care Professionals and Patients
  Michael A. Thompson, MD, PhD - Chair
- Panel Question and Answer
Session Title: Understanding, Exploring, and Looking at New and Future Developments in Non-Small Cell Lung Cancer Immunotherapy

Session Type: Education Session

Track: Lung Cancer

Time: 4:45 PM - 6:00 PM

Location: E Hall D1

- The Concepts and Basic Science of Immunotherapy As It Specifically Pertains to Lung Cancer
  *Drew M. Pardoll, MD, PhD*

- Updates and Ongoing Clinical Trials in Immunotherapy
  *Laura Quan Man Chow, MD, FRCPC*

- Future Directions in Immunotherapies: Rationale and Risk
  *Scott N. Gettinger, MD - Chair*

- Panel Question and Answer

Session Title: Nonrhabdomyosarcoma Soft Tissue Sarcomas in Children and Young Adults - Ticketed Session

Session Type: Meet the Professor Session

Track: Pediatric Oncology

Time: 4:45 PM - 6:00 PM

Location: E451a

- Systematic Approach to the Management of Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma
  *Sheri L. Spunt, MD, MBA*

- Radiation Therapy for Nonrhabdomyosarcoma Soft Tissue Sarcoma
  *Matthew J. Krasin, MD*

Session Title: Therapeutic Advances in Myeloproliferative Neoplasms: Focus on Myelofibrosis and Chronic Myelogenous Leukemia - Ticketed Session

Session Type: Clinical Problems in Oncology Session

Track: Leukemia, Myelodysplasia, and Transplantation

Time: 4:45 PM - 6:00 PM

Location: E451b

- Practical Issues in Managing Chronic Myelogenous Leukemia: Compliance and Cost (and Cure?)
  *Jerald P. Radich, MD*

- How I Treat Patients with Myelofibrosis
  *Francisco Cervantes, MD - Chair*
**Session Title:** Post-Plenary Discussion II: Gastrointestinal Cancer  
**Session Type:** Special Session  
**Track:** Special Session  
**Time:** 5:00 PM - 5:30 PM  
**Location:** S100a  
- Chair  
  *Georgios Lypas, MD - Chair*  
- Speaker  
  *Alan P. Venook, MD*  
- Speaker  
  *Josep Tabernero, MD, PhD*  
- Speaker  
  *Leonard Saltz, MD*

**Session Title:** Post-Plenary Discussion III: Breast Cancer  
**Session Type:** Special Session  
**Track:** Special Session  
**Time:** 5:30 PM - 6:00 PM  
**Location:** S100bc  
- Speaker  
  *Eric P. Winer, MD - Chair*  
- Speaker  
  *Martine J. Piccart-Gebhart, MD, PhD*  
- Speaker  
  *Olivia Pagani, MD*  
- Speaker  
  *Nancy E. Davidson, MD*  
- Speaker  
  *Lowell E. Schnipper, MD*